

Synthesis of Lactams by Isomerization of Oxindoles Substituted at C-3 by an ω -Amino Chain

Daad Sarraf, Nicolas Richy, and Joëlle Vidal*

Chimie et photonique moléculaires, Institut des Sciences Chimiques de Rennes, Université de Rennes 1, CNRS-UMR 6226, Campus de Beaulieu, 35042 Rennes Cedex, France

Supporting Information

ABSTRACT: Oxindoles substituted at N-1 by electron-withdrawing groups and at C-3 by ω -amino chains of various lengths undergo mild and easy isomerization to new 5- to 12-membered lactams in good yields (30–96%). As efficient asymmetric syntheses of diversely 3,3-disubstituted oxindoles are currently developed, this isomerization provides a new and valuable access to medium-sized lactams α -substituted with a quaternary asymmetric carbon bearing a 2-aminophenyl residue.

INTRODUCTION

The 3,3-disubstituted oxindole scaffold, which is present in a large number of natural and synthetic compounds with significant biological activities, is currently an important target for the development of very efficient asymmetric synthesis methods. Furthermore, these methods allow the introduction of a very wide diversity of substituents at C-3. Among the natural products bearing this scaffold, TMC-95A has attracted our interest because it is a potent proteasome inhibitor (Scheme 1).

We showed that linear mimics of TMC-95A, which contained the 3-hydroxyoxindolyl alanine residue, retained the proteasome inhibitory activity.⁴ In the course of their synthesis, we observed that the 2-(3-oxindolyl)ethylamine core slowly isomerized to (2-aminophenyl)-2-butyrolactam (25%)

Scheme 1. Structures of Some Proteasome Inhibitors and Isomerization of 3-(2-Aminoethyl)oxindole to 2-(2-Aminophenyl) γ -Lactam Followed by Acidic Transformation into Protonated Starting Material

conversion after 18 h at room temperature, neat liquid, Scheme 1). Such an isomerization has occasionally been described^{5,6} and has complicated the structure determination of the natural products donoxaridine⁷ and chimonamidine.^{7b,8} We also took advantage of the reported instability of the 2-(2-aminophenyl)- γ -lactam scaffold in acidic medium that rapidly led to the protonated form of the starting 2-(3-oxindolyl)ethylamine (Scheme 1). 5d,e,9 To the best of our knowledge, isomerization of oxindoles substituted at C-3 with longer ω -amino chains has not been studied. Since ring-closure reactions leading to 7- to 10-membered lactams are generally difficult, this isomerization may be valuable for the formation of medium-sized lactams that find widespread use in organic chemistry (key intermediates, core structures of natural products, or biologically active compounds). 10,11 We reasoned that substituting the oxindole nitrogen by an electron-withdrawing group (EWG) would enhance the electrophilicity of the oxindole carbonyl and favor the isomerization while disfavoring the reverse reaction in acidic medium due to poor nucleophilicity (Scheme 2).

Scheme 2. General Scheme for Isomerization of Oxindole 1 to Lactam 2 and Structures of Precursors 3 or 4

Received: August 27, 2014
Published: October 22, 2014

Herein we report the easy formation of 5- to 12-membered lactams 2 from oxindoles 1 substituted at N-1 by EWG and at C-3 by ω -amino chains of various lengths (Scheme 2). The isomerization of two families of oxindoles 1, obtained from nitro compounds 3 or N-Boc-protected derivatives 4, was studied (Scheme 2). Lactams 2 proved to be stable in acidic medium, provided EWG is also stable. Owing to the recent significant advances in the asymmetric synthesis of the 3,3-disubstituted oxindole scaffold, this isomerization provides a new access to lactams, substituted with a α -quaternary asymmetric carbon. 10

■ RESULTS AND DISCUSSION

We began our investigation by generating the amino group in 1 from the corresponding nitroethyl derivatives 3, which were readily prepared by Michael addition of 3-oxindoles 5 to nitroolefins¹² followed by functionalization of 6 by EWG (Scheme 3).

Scheme 3. Synthesis of Compounds 3

^aEWG-X = Ac-Cl, Boc-OBoc, or Ms-Cl. ^bCompound **6a** (dr > 20/1)^{12e} was prepared according to the literature. ^cSee the formulas of R¹, R², and EWG in Table 2. Compound **3d**^{12e} was prepared according to the literature. Nonracemic **3e**^{12c} and **3f**^{12b} have been described.

Reduction conditions were optimized using the N-acetyl compound 3a (Table 1). Catalytic hydrogenation using

Table 1. Reduction of Nitro Derivative 3a

3h, then NaBH₄ (6 equiv), rt

Ph. NO₂
Ph. NN X

NH 2a:
$$X = H$$
Ac 7: $X = OH$

entry conditions ratio (%)

1	H ₂ , Pd/C, MeOH, 18h, rt	1/4	15	74
2	H ₂ , Pd/C, MeOH/AcOH, 18h, rt	1/4		
3	NaBH ₄ (16 equiv), NiCl ₂ (2 equiv), EtOH, 3h, rt	3/2		
4	NaBH. (16 equiv), NiCl. (2 equiv), EtOH.	>20/1	56	

 $^a\mathrm{Ratio}$ determined by $^1\mathrm{H}$ NMR analysis of the crude mixture (solvent DMSO). $^b\mathrm{Isolated}$ yield.

palladium on charcoal was first carried out (entries 1 and 2). The crude product contained a 1/4 mixture of γ -lactam 2a and cyclic hydroxamic acid derivative 7, which was isolated in 74% yield. Compound 7 resulted from the isomerization of the intermediate hydroxylamine formed from the nitro group. Adding acetic acid did not favor its further reduction into 2a.

We then used sodium borohydride in the presence of NiCl₂ (entries 3 and 4). ^{12a,i} Complete conversion of **3a** was observed after 3 h at room temperature, leading to a 3/2 mixture of **2a** and 7. Adding an excess of sodium borohydride induced further reduction of 7 and allowed isolation of **2a** in 56% yield.

We then examined the substrate scope of different N-EWG-substituted nitrooxindoles 3a-g using $NaBH_4/NiCl_2$ as the reducing agent (Table 2). Lactams 2a-f (EWG = Ac or Boc)

Table 2. Synthesis of γ -Lactams 2a-g by Reduction of Oxindoles 3

entry	3	2	EWG	\mathbb{R}^1	\mathbb{R}^2	yield a (%)
1	3a	2a	Ac	Ph	Ph	56
2	3b	2b	Ac	Ph	Н	64
3	3c	2c	Ac	Me	Н	58
4	3d	2d	Boc	Ph	Ph	52
5	3e	2e	Boc	Ph	Н	55
6	3f	2f	Boc	Me	Н	57
7	3g	2g	Ms	Ph	Ph	71
^a Isolated yield.						

were isolated in 52-64% yield (entries 1-6). A higher yield in 2g was obtained from 3g, which was substituted by the better electron-withdrawing substituent Ms (entry 7).

These γ -lactams 2a-g were characterized by 1H NMR spectroscopy using CD₃SOCD₃ as solvent rather than CDCl₃. The NH-EWG chemical shifts were in the 9.1–10.2 ppm range. Noteworthy were the shape of the NH γ -lactam signal which appeared as a broad singlet instead of a triplet, a feature that has been generally observed in CD₃SOCD₃, 14 and the unusual chemical shift (1.24–1.38 ppm) of the *N*-Ac group in 2a, b. Fortunately, the single-crystal X-ray structure of lactam 2b was obtained and allowed interpretation of these apparent discrepancies (see the Supporting Information).

The structure showed the presence of the Ac group in the magnetic shielding region of the benzene ring at C-3. Lactam NH–CH dihedral angles were ca. 60° , leading to small vicinal coupling constants in the ^{1}H NMR. Finally, we noticed the stability of butyrolactams 2 in acidic medium: the ^{1}H NMR spectrum of 2b (c = 0.05 M, $CD_{3}SOCD_{3}$) remained unchanged after 4 days at room temperature in the presence of excess trifluoracetic acid (3 equiv).

In order to study the influence of the ω -amino side chain length on the isomerization, we prepared Boc-amino precursors 4a-n from 3-hydroxyoxindoles 8 (Table 3).

N-Boc-aminoalkanoic acids (n = 1-5) were efficiently coupled to hindered 3-hydroxyoxindole 8a using the Steglich conditions, with DCC resulting in better yields than 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide (EDC) (entries 1–5). Compounds substituted by donor or acceptor substituents on the aromatic ring were synthesized (entries 6–8). Different EWG groups (Ac, Cbz, and CONMe₂) were easily introduced in 3-hydroxy-3-cyanomethyl derivatives 8d–f (entries 9–12). Reaction of 8d–f with DCC and *N*-Boc- β -alanine or *N*-Boc-aminohexanoic acid worked in good yields to give 4i–l (entries 9–12). However, addition of DMAP in the

Table 3. Synthesis of Oxindoles 4 Substituted at C-3 by ω -Boc-amino Side Chains of Varying Lengths

entry	8	4	EWG	\mathbb{R}^2	\mathbb{R}^1	n	yield ^a (%)
1	8a	4a	Ac	Н	CH ₃	1	69 ^b
2	8a	4b	Ac	Н	CH_3	2	95 ^b
3	8a	4c	Ac	Н	CH_3	3	78^b
4	8a	4d	Ac	Н	CH_3	4	95 ^b
5	8a	4e	Ac	Н	CH_3	5	97 ^b
6	8b	4f	Ac	F	CH_3	2	60^{b}
7	8c	4g	Ac	CH_3O	CH_3	2	91 ^b
8	8c	4h	Ac	CH_3O	CH_3	5	78^b
9	8d	4i	Ac	Н	CH_2CN	2	59
10	8d	4j	Ac	Н	CH_2CN	5	98
11	8e	4k	Cbz	Н	CH ₂ CN	5	72
12	8f	4l	$CON(CH_3)_2$	Н	CH ₂ CN	5	73
^a Isolated yield. ^b DMAP was added.							

synthesis of 4i–l resulted in the formation of unidentified products. Derivatives 4m–n containing 10-amino or 19-amino oxyethylene chains were obtained using *N*-Boc-amino acids 9¹⁷ (Scheme 4). Boc-amino compound 4o that did not bear an ester functionality at the quaternary junction was also prepared in three steps from nitroethyl compound 6d (Scheme 4).

Scheme 4. Synthesis of Precursors 4m-o

Finally, Boc-amino precursors 4a-o were deprotected using anhydrous hydrogen chloride (Scheme 5). Integration of the ¹H NMR signals of the resulting chlorhydrate (solvent CD₃SOCD₃) also showed the formation of up to 40% of the expected lactam 2, indicating that the isomerization could occur even in acidic medium. Further treatment overnight by triethylamine at room temperature led to original 7- to 12membered lactams 2h-r, which were isolated in 30-96% yields (Scheme 5). Unidentified products were obtained from 4a and 4l after prolonged heating at 45 °C. The side chain in 4a was probably too short to induce a favorable overlap of the amine HOMO and the carbonyl LUMO. As 4j and 4k successfully gave 2p and 2q, the failure of 4l to react similarly may indicate that the electron-withdrawing effect of the carbamoyl group was not strength enough in order to promote the isomerization. The basic form of deprotected 4n remained stable, failing to

Scheme 5. Synthesis of Lactams 2h-s

^aIsolated yield. ^bCrude product was a 3/2 mixture of 2j and δ -valerolactam.

give the corresponding 21-membered macrocycle. The competing attack of the carbonyl of the ester function instead of the oxindole one was observed only in the case of derivative 4d leading to a 3/2 mixture of the nine-membered lactam 2j and the six-membered δ -valerolactam. Fortunately, the nine-membered lactam 2s featuring the cyclic core found in cyclic peptides that inhibit protein tyrosine phosphatase from *Mycobacterium tuberculosis*¹⁸ was obtained in a good yield from 4o. Similarly to γ -lactam 2b, medium-sized lactam 2k proved to be stable in the presence of trifluoroacetic acid (4 equiv, no change after 6 days at rt).

CONCLUSION

In summary, we have developed the easy transformation of oxindole derivatives 3 and 4 substituted at C-3 by an ω -amino chain of varying length into γ -lactams $2\mathbf{a}-\mathbf{g}$ and medium-sized lactams $2\mathbf{h}-\mathbf{s}$. The reactions are easy to conduct and occur under mild conditions, and the yields are good. The use of building blocks 3 or 4 is a new route to lactam synthesis ¹⁰ and may allow configuration control of the quaternary carbon α to the carbonyl, using the asymmetric methods currently developed for the synthesis of C-3-disubstituted oxindoles. As medium-sized lactams $2\mathbf{h}-\mathbf{r}$ display unknown depsipeptide cores, this method may find applications in the discovery of new macrolactams of therapeutic interest. ^{10a,19}

■ EXPERIMENTAL SECTION

Methods and Materials. Commercially available reagents were used without further purification. Reagent-grade solvents were used for extraction and flash chromatography. DCM was stabilized with amylene. Dry solvents were distilled from the appropriate drying reagents immediately before use. Yields refer to chromatographically and spectroscopically homogeneous materials. Reactions were monitored by thin-layer chromatography carried out on silica gel

aluminum sheets (60F-254) using UV light as a visualizing agent followed by 15% ethanolic phosphomolybdic acid and heat or 0.2% ethanolic ninhydrin and heat as developing agent. Column chromatography was performed on silica gel 60, 0.063–0.200 mm. $^1\mathrm{H}$ NMR and $^{13}\mathrm{C}$ NMR spectra were recorded at room temperature at, respectively, 300 and 75.5 MHz frequencies. Chemical shifts were reported in ppm (δ units), and residual nondeuterated solvent was used as internal reference. Assignments of $^{13}\mathrm{C}$ signals were determined using DEPT experiments. Mass spectrometry accurate mass data (HRMS) were obtained from a Q-TOF spectrometer using an electrospray source (ESI). Melting points were determined using a Griffin melting point apparatus and are uncorrected. Compounds 5a,b were commercially available.

Procedure for the Synthesis of Compounds 2a–g. To a mixture of nitro-oxindole 3a (112.4 mg, 0.281 mmol) and NiCl $_2$ (69.1 mg, 0.53 mmol) in absolute ethanol (1 mL) was added sodium borohydride (170 mg, 4.5 mmol). The black mixture was stirred at room temperature. The progress of the reaction was monitored by TLC. Three further portions of sodium borohydride (50 mg, 1.3 mmol) were added after stirring for 3, 5, and 7 h, respectively. After dilution by CH $_2$ Cl $_2$ (30 mL), the mixture was washed by 10% aqueous ammonium chloride. The organic phase was concentrated in vacuo, and the residue was purified by chromatography over silica gel (3.5 g, eluent CH $_2$ Cl $_2$) to afford lactam 2a as a white solid (58.5 mg, 56% yield).

N-(2-(rel-(3S,4S)-2-Oxo-3,4-diphenylpyrrolidin-3-yl)phenyl)acetamide (2a): ¹H NMR (300 MHz, DMSO- d_6) δ 1.24 (s, 3H), 3.52 (dd, J = 10.5, 5 Hz, 1H), 3.81 (dd, J = 10.5, 6.5 Hz, 1H), 4.64 (t, J = 6)Hz, 1H), 6.62 (m, 2H), 6.78-6.82 (m, 2H), 6.87-7.01 (m, 6H), 7.25-7.36 (m, 2H), 7.51 (dd, I = 7.8 Hz, 1.8 Hz, 1H), 8.08 (d, I = 7.8Hz, 1H), 8.92 (s, 1H), 10.03 (s, 1H); 1 H NMR (300 MHz, CDCl₃) δ 1.33 (s, 3H), 3.66 (dd, J = 9.9, 5.4 Hz, 1H), 3.86 (dd, J = 9.9, 7.2 Hz, 1H), 4.49 (t, I = 6.2 Hz, 1H), 6.69 (m, 5H), 6.97 (m, 6H), 7.22 (dd, I= 7.8, 1.5 Hz, 1H), 7.31 (td, J = 7.6, 1.2 Hz, 1H), 7.60 (dd, J = 7.8, 1.5 Hz, 1H), 7.84 (d, J = 7.5 Hz, 1H), 9.64 (s, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 23.2 (CH₃), 45.9 (CH₂), 50.0 (CH), 61.9(C), 124.6 (CH), 126.4 (CH), 126.8 (CH), 127.1 (CH), 127.7 (CH), 127.9 (CH), 128.0 (CH), 128.3 (CH), 128.6 (CH), 129.1 (CH), 132.5 (C), 137.80 (C), 137.85 (C), 138.7 (C), 168.1 (C), 179.1 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]⁺ calcd for $C_{24}H_{22}N_2O_2Na$ 393.1579, found 393.1579; R_f (AcOEt) 0.46; mp 242-246 °C.

N-(2-(2-Oxo-3-phenylpyrrolidin-3-yl)phenyl)acetamide (2b): yield 69 mg (64%); crystalline solid; ¹H NMR (300 MHz, DMSO- d_6) δ 1.38 (s, 3H), 2.35 (ddd, J = 13.5, 8 Hz, 8 Hz, 1H), 3.13 (ddd, J = 13.5, 6.0, 3 Hz, 1H), 3.29-3.49 (m, 2H), 7.04-7.07 (m, 2H), 7.23-7.41 (m, 5H), 7.58 (dd, J = 7.8, 1 Hz, 1H), 7.73 (dd, J = 7.8, 1 Hz, 1H), 8.60 (s, 1H), 10.19 (s, 1H); NMR signal attribution resulted from HMBC and HSQC experiments, see the Supporting Information for atom numbering; ¹H NMR (300 MHz, CDCl₃) δ 1.43 (s, 3H²²), 2.35 $(ddd, I = 13, 8, 8 Hz, 1H^8), 3.04 (ddd, I = 13, 6, 3 Hz, 1H^8), 3.34 (m,$ $(1.17)^{1}$, 3.46 (m, $1H^{9}$), 6.92 (br s, $1H^{10}$), 7.02–7.04 (m, $2H^{1,5}$), 7.12–7.23 (m, $4H^{15,3,2,4}$), 7.29 (ddd, J = 7.8, 7.8, 1.2 Hz, $1H^{16}$), 7.47 (d, J = 1.00) 7.2 Hz, 1H¹⁴), 7.62 (dd, J = 7.8, 1.2 Hz, 1H¹⁷), 9.82 (s, 1H¹⁹); ¹³C NMR (75.5 MHz, CDCl₃) δ 23.4 (C²²), 38.6 (C⁸), 39.8 (C⁹), 56.7 (C^7) , 124.7 (C^{15}) , 126.0 $(C^{1,5})$, 126.2 (C^{14}) , 126.8 (C^3) , 127.5 (C^{17}) , 128.6 (C^{16}), 128.7 ($C^{2,4}$), 131.1 (C^{13}), 137.5 (C^{18}), 143.4 (C^{6}), 168.3 (C^{20}) , 179.7 (C^{11}) ; HRMS (ESI-TOF, CH₃OH) m/z [M + Na]⁺ calcd for C₁₈H₁₈N₂O₂Na 317.1266, found 317.1268; R_f (1/1 AcOEt/ CH₂Cl₂) 0.28; mp 219-222 °C.

N-(2-(3-Methyl-2-oxopyrrolidin-3-yl)phenyl)acetamide (2c): yield 54 mg (58%); crystalline solid; 1 H NMR (300 MHz, DMSO- d_6) δ 1.45 (s, 3H), 2.03 (s, 3H), 2.09 (m, 1H), 2.63 (m, 1H), 3.22 (m, 1H), 3.29 (m, 1H), 7.14 (td, J = 7.8, 1.2 Hz, 1H), 7.25 (td, J = 7.8, 1.2 Hz, 1H), 7.41 (dd, J = 7.8, 1.2 Hz, 1H), 7.54 (dd, J = 7.8, 1.2 Hz, 1H), 8.09 (s, 1H), 10.39 (s, 1H); 1 H NMR (300 MHz, CDCl₃) δ 1.60 (s, 3H), 2.18 (m, 4H), 2.87 (m, 1H), 3.45 (m, 2H), 6.02 (broad s, 1H), 7.06 (t, J = 7.8 Hz, 1H), 7.22–7.27 (m, 2H), 7.83 (d, J = 7.8 Hz, 1H), 10.35 (broad s, 1H); 13 C NMR (75.5 MHz, CDCl₃) δ 22.4 (CH₃), 24.3 (CH₃), 36.7 (CH₂), 39.3 (CH₂), 47.5 (C), 125.1(CH), 126.0 (CH), 126.9 (CH), 128.1 (CH), 132.6 (C), 136.9 (C), 168.8 (C), 182.1 (C);

HRMS (ESI-TOF, CH₃OH) m/z [M + N₄]⁺ calcd for C₁₃H₁₆N₂O₂Na 255.1109, found 255.1108; R_f (MeOH/CH₂Cl₂ 1/9) 0.50; mp 160–165 °C.

tert-Butyl (2-(rel-(3S,4S)-2-oxo-3,4-diphenylpyrrolidin-3-yl)phenyl)carbamate (2d): yield 57 mg (52%); crystalline solid; ¹H NMR (300 MHz, DMSO- d_6) δ (two rotamers, 57/43 mixture) 1.07 and 1.20 (two s, 9H),3.51 (m, 1H), 3.77 (m, 1H), 4.49 and 4.61 (two t, J = 4 Hz, 1H), 6.59-7.41 (m, 14 H), 8.04 (d, J = 8 Hz, 0.43 H), 8.57(s, 0.57 H), 8.81 (s, 0.43 H), 9.13 (0.43 H); ¹H NMR (300 MHz, CDCl₃) δ (two rotamers, 57/43 mixture) 1.14 and 1.26 (9H, two s), 3.69 (m, 1H), 3.87 (m, 1H), 4.54 (t, J = 4 Hz, 1H), 6.33 (br s, 0.57)H), 6.70-7.67 (m, 14.43 H), 7.86 (d, J = 7.5 Hz, 0.57 H), 8.77 (s, 0.43H); 13 C NMR (75.5 MHz, CDCl₃) δ (two rotamers) 28.0 and 28.1 (CH₃), 45.8 and 45.9 (CH₂), 50.1 and 50.2 (CH), 61.2 and 61.8 (C), 78.7 and 79.2 (C), 123.0 (CH), 123.4 (CH), 126.3 (CH), 126.7 (CH), 127.0 (CH), 127.4 (CH), 127.5 (CH), 127.70 (CH), 127.75 (CH), 127.8 (CH), 127.9 (CH), 128.1 (CH), 128.2 (CH), 128.3 (CH), 128.8 (CH), 129.2 (CH), 130.0 (CH), 137.2 (C), 137.9 (C), 138.3 (C), 138.5 (C), 138.6 (C), 139.6 (C), 140.5 (C), 152.3 and 152.3 (C), 178.1 and 179.0 (C); HRMS (ESI-TOF, CH₃OH) m/z [M + Na]⁺ calcd for $C_{27}H_{28}N_2O_3Na$ 451.1998, found 451.2000; R_f (AcOEt/CH2Cl2 1/9) 0.50; mp 189-192 °C.

tert-Butyl (2-(2-oxo-3-phenylpyrrolidin-3-yl)phenyl)carbamate (2e): yield 60 mg (55%); crystalline solid; 1 H NMR (300 MHz, DMSO- d_6) δ 1.13 (s, 9H), 2.23 (m, 1H), 3.06 (m, 1H), 3.23 (m, 1H), 3.38 (m, 1H), 6.99 (d, J = 7.2 Hz, 1H), 7.12–7.42 (m, 7H), 7.64 (d, J = 7.6 Hz, 1H), 8.50 (s, 1H), 9.32 (s, 1H); 1 H NMR (300 MHz, CDCl₃) δ 1.14 (s, 9H), 2.41 (m, 1H), 3.03 (m, 1H), 3.34 (m, 1H), 3.46 (m, 1H), 5.81 (br s, 1H), 7.05–7.30 (m, 7H), 7.43 (d, J = 8 Hz, 1H), 7.56 (d, J = 8 Hz, 1H), 8.71 (br s, 1H); 13 C NMR (75.5 MHz, CDCl₃) δ 28.1 (CH₃), 38.4 (CH₂), 39.7 (CH₂), 56.6 (C), 79.0 (C), 123.7 (CH), 126.1 (CH), 126.2 (CH), 126.7 (CH), 128.4 (CH), 128.5 (CH), 128.5 (CH), 131.3 (C), 138.1 (C), 143.2 (C), 153.2 (C), 179.4 (C); HRMS (ESI-TOF, CH₃OH) m/z [M + Na]⁺ calcd for C₂₁H₂₄N₂O₃Na 375.1685, found 375.1688; R_f (1% Et₃N in 1/1 AcOEt/petroleum ether) 0.58; mp 182–185 °C.

tert-Butyl (2-(3-methyl-2-oxopyrrolidin-3-yl)phenyl)carbamate (2f): yield 59 mg (57%); crystalline solid; ¹H NMR (300 MHz, DMSO- d_6) δ 1.44 (s, 12 H), 2.08 (m, 1 H), 2.72 (m, 1H), 3.17–3.30 (m, 2 H), 7.09 (ddd, J = 7.8, 7.8, 1.5 Hz, 1H), 7.24 (ddd, J = 7.8, 7.8, 1.5 Hz, 1H), 7.50 (dd, J = 7.8, 1.5 Hz, 1H), 7.50 (dd, J = 7.8, 1.5 Hz, 1H), 8.11 (s, 1H), 9.86 (s, 1 H); ¹H NMR (300 MHz, CDCl₃) δ 1.18 (s, 3H), 1.44 (s, 9H), 2.17 (m, 1H), 2.73 (m, 1H), 3.46 (m, 2H), 5.69 (br s, 1H), 7.03 (t, J = 7.6 Hz, 1H), 7.29 (m, 2H), 7.62 (d, J = 8 Hz, 1H), 8.88 (br s, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 22.1 (CH₃), 28.4 (CH₃), 36.6 (CH₂), 39.3 (CH₂), 47.4 (C), 79.5 (C), 124.5 (CH), 126.1 (CH), 126.7 (CH), 127.9 (CH), 133.4 (C), 137.1 (C), 154.1 (C), 182.1 (C); HRMS (ESI, CH₃OH) calcd for C₁₆H₂₂N₂O₃Na [(M + Na)⁺] 313.1528, found 313.1525; R_f (1/1/0.01 AcOEt/petroleum ether/Et₃N) 0.22; mp 134–138 °C.

N-(2-(rel-(3S,4S)-2-Oxo-3,4-diphenylpyrrolidin-3-yl)phenyl)methanesulfonamide (2g): yield 45 mg (71%); crystalline solid; ¹H NMR (300 MHz, DMSO- d_6) δ 1.85 (s, 3H), 3.47 (dd, J = 10.8, 2.5 Hz, 1H), 3.81 (dd, J = 10.8, 6.3 Hz, 1H), 4.63 (m, 1H), 6.74-6.75 (m, 2H), 6.81-6.85 (m, 2H), 7.00-7.07 (m, 6H), 7.29 (td, J = 7.8, 1.2 Hz, 1H), 7.39 (td, J = 8.4, 1.2 Hz, 1H), 7.63 (dd, J = 7.8, 1.2 Hz, 1H), 8.13 $(d, J = 7.2 \text{ Hz}, 1\text{H}), 9.06 (s, 1\text{H}), 10.49(s, 1\text{H}); {}^{1}\text{H NMR} (300 \text{ MHz},$ CDCl₃) δ 1.80 (s, 3H), 3.61 (dd, J = 10.2, 4.2 Hz, 1H), 3.87 (dd, J = 10.2, 6.6 Hz, 1H), 4.42 (dd, *J* = 6.3, 4.3 Hz, 1H), 6.48 (s, 1H), 6.71-6.79 (m, 4H), 6.95-6.99 (m, 6H), 7.18 (m, 1H), 7.30 (t, J = 7.5 Hz,1H), 7.77 (d, J = 7.8 Hz, 1H), 7.86 (d, J = 8.1 Hz, 1H), 10.08 (s, 1H); 13 C NMR (75.5 MHz, CDCl₃) δ 38.8 (CH₃), 46.2 (CH₂), 51.1 (CH), 61.8 (C), 122.3 (CH), 123.8 (CH), 127.0 (CH), 127.1 (CH), 127.2 (CH), 128.0 (CH), 128.2 (CH), 128.5 (CH), 129.2 (CH), 129.3 (CH), 131.0 (C), 137.9 (C), 138.2 (C), 139.4 (C), 178.7 (C); HRMS (ESI-TOF, CH₃OH) m/z [M + Na]⁺ calcd for C₂₃H₂₂N₂O₃NaS 429.1249, found 429.1250; R_f (AcOEt/CH₂Cl₂ 1/9) 0.30; mp 195-198 °C

Procedure for the Synthesis of Compounds 2h-r. To a solution of Boc derivative 4b (124.5 mg, 0.331 mmol) in AcOEt (0.2

mL) was added a 3 M solution of anhydrous HCl in AcOEt (0.35 mL, 1.05 mmol). The mixture was stirred at room temperature overnight. The solvent was removed in vacuo. To the resulting solid were added CH_2Cl_2 (0.6 mL) and trietylamine (90 μL , 0.65 mmol). The mixture was stirred for 8 h at room temperature, diluted with CH_2Cl_2 (10 mL), and washed with aqueous 10% citric acid. The organic phase was dried over sodium sulfate and concentrated in vacuo. Purification by chromatography over silica gel (6.3 g, eluent 1% MeOH in AcOEt) afforded lactam **2h** as a white solid (87.8 mg, yield 96%).

N-(2-(2-Methyl-3,7-dioxo-1,4-oxazepan-2-yl)phenyl)acetamide (*2h*): ¹H NMR (300 MHz, DMSO- d_6) δ 1.48 (s, 3H), 1.76 (s, 3H), 2.47 (m, 2H), 3.14 (m, 2H), 6.83 (d, J=9 Hz, 1H), 6.96 (t, J=9 Hz, 1H), 7.19–7.23 (m, 2H), 7.90 (br s, 1H), 10.56 (s, 1H); ¹H NMR (300 MHz, CDCl₃, c=0.24 mol l⁻¹) δ 1.55 (s, 3H), 1.80 (s, 3H), 2.39–2.59 (m, 2H), 3.26–3.48 (m, 2H), 6.34 (br s, 1H), 6.81 (d, J=7.8 Hz, 1H), 6.96 (t, J=7.2 Hz, 1H), 7.12–7.20 (m, 2H), 8.93 (s, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 23.0 (CH₃), 23.2 (CH₃), 33.8 (CH₂), 34.9 (CH₂), 78.1 (C), 110.5 (CH), 122.3 (CH), 122.8 (CH), 129.3 (C), 129.7 (CH), 140.4 (C), 170.6 (C), 171.1 (C), 177.3 (C); HRMS (ESI-TOF, CH₃OH) m/z [M + Na]⁺ calcd for C₁₄H₁₆N₂O₄Na 299.1008, found 299.1008; R_f (MeOH/AcOEt 5/95) 0.26; mp 115–119 °C.

N-(2-(2-Methyl-3,8-dioxo-1,4-oxazocan-2-yl)phenyl)acetamide (2i). Starting from Boc derivative 4c (208.6 mg, 0.534 mmol), the general procedure afforded lactam 2i as a viscous oil (105 mg, yield 68%): ¹H NMR (300 MHz, DMSO- d_6) δ 1.48 (s, 3H), 1.55 (m, 2H), 1.77 (s, 3H), 2.32 (t, J = 7.2 Hz 2H), 2.97 (m, 2H), 6.83 (d, J = 7.5 Hz, 1H), 6.96 (t, J = 7.5 Hz, 1H), 7.20–7.26 (m, 2H), 7.82 (br s, 1H), 10.54 (s, 1H); ¹H NMR (300 MHz, CDCl₃, c = 0.14 mol l⁻¹) δ 1.54 (s, 3H), 1.69 (m, 2H), 1.83 (s, 3H), 2.29 (m, 2H), 3.14 (m, 2H), 6.10 (br s, 1H), 6.80 (d, J = 7.8 Hz, 1H), 6.95 (t, J = 7.5 Hz, 1H), 7.10–7.17 (m, 2H), 8.82 (s, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 23.1 (CH₃), 23.3 (CH₃), 24.3 (CH₂), 31.2 (CH₂), 38.7 (CH₂), 77.8 (C), 110.5 (CH), 122.3 (CH), 122.8 (CH), 129.4 (C), 129.7 (CH), 140.5 (C), 170.8 (C), 171.8 (C), 177.3 (C); HRMS (ESI-TOF, CH₃OH) m/z [M + Na]⁺ calcd for C₁₅H₁₈N₂O₄Na 313.1164, found 313.1159; R_f (AcOEt) 0.15

N-(2-(2-Methyl-3,9-dioxo-1,4-oxazonan-2-yl)phenyl)acetamide (2j). Starting from Boc derivative 4d (249 mg, 0.616 mmol), the general procedure afforded a crude product containing a 3/2 mixture of expected lactam 2j and δ -valerolactam. Purification by chromatography over silica gel (8 g, eluent AcOEt) afforded lactam 2j as a viscous oil (56.2 mg, yield 30%): 1 H NMR (300 MHz, DMSO- d_{κ}) δ 1.30-1.43 (m, 4H), 1.47 (s 3H), 1.77 (s, 3H), 2.31 (t, J = 6 Hz, 2H), 2.98 (m, 2H), 6.83 (d, J = 8 Hz, 1H), 6.95 (t, J = 7.5 Hz, 1H), 7.20 (m, 2H), 7.79 (broad s, 1H), 10.53 (s, 1H); ¹H NMR (300 MHz, CDCl₃, c = 0.26 mol l^{-1}) δ 1.37–1.52 (m, 4H), 1.53 (s, 3H), 1.85 (s, 3H), 2.27 (m, 2H), 3.09 (m, 2H), 6.10 (br s, 1H), 6.79 (d, J = 7.8 Hz, 1H), 6.94 $(t, J = 7.2 \text{ Hz}, 1\text{H}), 7.10 - 7.18 \text{ (m, 2H)}, 8.99 \text{ (s, 1H)}; {}^{13}\text{C NMR} (75.5)$ MHz, CDCl₃) δ 21.9 (CH₂), 23.0 (CH₃), 23.2 (CH₃), 28.3 (CH₂), 33.1 (CH₂), 38.9 (CH₂), 77.6 (C), 110.5 (CH), 122.1 (CH), 122.6 (CH), 129.4 (CH), 129.5 (C), 140.6 (C), 170.6 (C), 171.8 (C), 177.3 (C); HRMS (ESI-TOF, CH₃OH) m/z [M + Na]⁺ calcd for $C_{16}H_{20}N_2O_4Na$ [(M + Na)⁺] 327.1320, found 327.1321; R_f (MeOH/AcOEt 1/9) 0.57.

N-(2-(2-Methyl-3,10-dioxo-1,4-oxazecan-2-yl)phenyl)acetamide (2k). Starting from Boc derivative 4e (140.4 mg, 0.335 mmol), the general procedure afforded lactam 2k as an amorphous solid (67.2 mg, yield 63%): ¹H NMR (300 MHz, DMSO- d_6) δ 1.18 (m, 2H), 1.34 (m, 2H), 1.42 (m, 2H), 1.47 (s, 3H), 1.78 (s, 3H), 2.29 (t, J = 7.2 Hz, 2H), 2.94, 2.99 (ABq, J_{AB} = 6.7 Hz, 2H), 6.83 (dd, J = 8.1, 1 Hz, 1H), 6.96 (td, J = 8, 1 Hz, 1H), 7.20–7.26 (m, 2H), 7.76 (br s, 1H), 10.53 (s, 1H); ¹H NMR (300 MHz, CDCl₃, c = 0.31 mol l⁻¹) δ 1.24 (m, 2H), 1.38 (m, 2H), 1.38 (m, 2H), 1.41 (s, 3H), 1.86 (s, 3H), 2.25 (m, 2H), 3.09, 3.14 (ABq, J_{AB} = 6.5 Hz, 2H), 6.20 (br s, 1H), 6.79 (d, J = 7.8 Hz, 1H), 6.93 (t, J = 7.5 Hz, 1H), 7.10–7.17 (m, 2H), 9.03 (s, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 23.1 (CH₃), 23.3 (CH₃), 24.2 (CH₂), 25.8 (CH₂), 28.7 (CH₂), 33.5 (CH₂), 39.1 (CH₂), 77.7 (C), 110.6 (CH), 122.2 (CH), 122.6 (CH), 129.6 (C), 129.6 (CH), 140.7 (C), 170.7 (C), 171.9 (C), 177.3 (C); HRMS (ESI-TOF, CH₃OH) m/z

 $[M + Na]^+$ calcd for $C_{17}H_{22}N_2O_4Na$ 341.1477, found 341.1475; R_f (AcOEt) 0.23.

N-(4-Fluoro-2-(2-methyl-3,7-dioxo-1,4-oxazepan-2-yl)phenyl)acetamide (21). Starting from Boc derivative 4f (105.7 mg, 0.268 mmol), the general procedure afforded lactam 21 as an amorphous solid (37.86 mg, yield 48%): 1 H NMR (300 MHz, DMSO- d_{6}) δ 1.49 (s, 3H), 1.76 (s, 3H), 2.49–2.53 (m, 2H), 3.13–3.23 (m, 2H), 6.82 (dd, J = 8.4, 4.2 Hz, 1H), 7.06 (ddd, J = 11.1, 8.4, 2.7 Hz, 1H), 7.22(dd, J = 8.1, 2.7 Hz, 1H), 7.91 (t, J = 5.3 Hz, 1H), 10.59 (s, 1H); ¹H NMR (300 MHz, CDCl₃) δ 1.55 (s, 3H), 1.83 (s, 3H), 2.42–2.62 (m, 2H), 3.29–3.49 (m, 2H), 6.28 (t, J = 5.6 Hz, 1H), 6.78 (dd, J = 9.3, 4.2 Hz, 1H), 6.75-6.90 (m, 2H), 8.97 (s, 1H); ¹³C NMR (75.5 MHz, $CDCl_3$) δ 23.0 (CH₃), 23.2 (CH₃), 33.8 (CH₂), 35.0 (CH₂), 78.2 (d, I = 2 Hz, C), 110.5 (d, J = 25 Hz, CH), 111.3 (d, J = 8 Hz, CH), 116.1 (d, J = 23 Hz, CH), 130.8 (d, J = 8 Hz, C), 136.3 (d, J = 3 Hz, C),159.2 (d, J = 242 Hz, C), 170.7 (C), 171.2 (C), 177.2 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]⁺ calcd for $C_{14}H_{15}FN_2O_4Na$ 317.0914, found 317.0913; R_f (AcOEt) 0.14.

N-(*4*-Methoxy-2-(2-methyl-3,7-dioxo-1,4-oxazepan-2-yl)phenyl)-acetamide (2m). Starting from Boc derivative 4g (183.0 mg, 0.450 mmol), the general procedure afforded lactam 2m as an amorphous solid (56.5 mg, yield 41%): ¹H NMR (300 MHz, DMSO- d_6) δ 1.47 (s, 3H), 1.76 (s, 3H), 2.47 (m, 2H), 3.18 (m, 2H), 3.71 (s, 3H), 6.73–6.81 (m, 2H), 6.91 (s, 1H), 7.90 (broad s, 1H), 10.36 (s, 1H); ¹H NMR (300 MHz, CDCl₃, $c = 0.12 \text{ mol } l^{-1}$) δ 1.55 (s, 3H), 1.82 (s, 3H), 2.39–2.62 (m, 2H), 2.28–2.50 (m, 2H), 3.71 (s, 3H), 6.30 (broad s, 1H), 6.69–6.74 (m, 3H), 8.62 (s, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 23.1 (CH₃), 23.4 (CH₃), 33.9 (CH₂), 35.0 (CH₂), 55.8 (CH₃), 78.5 (C), 109.6 (CH), 111.0 (CH), 114.0 (CH), 130.7 (C), 133.5 (C), 156.1 (C), 170.6 (C), 171.2 (C), 177.2 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]⁺ calcd for C₁₅H₁₈N₂O₅Na 329.1113, found 329.1112; R_f (1% MeOH in AcOEt) 0.10.

N-(4-*Methoxy-2-*(2-*methyl-3*,10-*dioxo-1*,4-oxazecan-2-*yl)*-*phenyl)acetamide* (2*n*). Starting from Boc derivative 4h (181.9 mg, 0.405 mmol), the general procedure afforded lactam 2n as a gum (68.4 mg, yield 48%): ¹H NMR (300 MHz, DMSO- d_6) δ 1.21–1.47 (m, 9H), 1.77 (s, 3H), 2.30 (m, 2H), 2.97 (m, 2H), 3.70 (s, 3H), 6.73–6.81 (m, 2H), 6.88 (s, 1H), 7.78 (broad s, 1H), 10.36 (s, 1H); ¹H NMR (300 MHz, CDCl₃, c = 0.32 mol l⁻¹) δ 1.18–1.55 (m, 9H), 1.87 (s, 3H), 2.20 (m, 2H), 3.12 (m, 2H), 3.69 (s, 3H), 6.28 (broad s, 1H), 6.66–6.71 (m, 3H), 8.99 (broad s, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 23.0 (CH₃), 23.4 (CH₂), 24.1 (CH₂), 25.8 (CH₂), 28.7 (CH₂), 33.4 (CH₂), 39.1 (CH₂), 55.7 (CH₃), 78.0 (C), 109.5 (CH), 111.0 (CH), 113.8 (CH), 130.9 (C), 133.9 (C), 155.9 (C), 170.8 (C), 171.9 (C), 177.3 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]⁺ calcd for C₁₈H₂₄N₂O₃Na 371.1583, found 371.1583; R_f (MeOH/AcOEt 5/95) 0.28.

N-(2-(2-(Cyanomethyl)-3,7-dioxo-1,4-oxazepan-2-yl)phenyl)acetamide (20). Starting from Boc derivative 4i (101.8 mg, 0.254 mmol), the general procedure afforded lactam 20 as a white solid (36.7 mg, yield 48%): ¹H NMR (300 MHz, DMSO- d_6) δ 1.76 (s, 3H), 2.54 (m,2H), 3.17 (m,2H), 3.29 (s,2H), 6.89 (d,J=7.5 Hz,1H), 7.04 (t,J=7.5 Hz,1H)= 7.5 Hz, 1H, 7.30 (t, J = 7.5 Hz, 1H), 7.38 (d, J = 7.5 Hz, 1H), 7.91(br s, 1H), 10.88 (s, 1H); 1 H NMR (300 MHz, CDCl₃) δ 1.84 (s, 3H), 2.54 (m,2H), 2.69, 3.00 (ABq, J_{AB} = 16.8 Hz, 2H), 3.39 (m, 2H), 6.26 (t, J = 6.5 Hz, 1H), 6.88 (d, J = 7.5 Hz, 1H), 7.04 (t, J = 7.5 Hz, 1H), 7.28 (t, J = 7.5 Hz, 1H), 7.38 (d, J = 7.5 Hz, 1H), 9.09 (s, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 23.1 (CH₃), 26.2 (CH₂), 33.7 (CH₂), 34.9 (CH₂), 75.7 (C), 111.1 (CH), 114.5 (C), 123.5 (CH), 123.6 (CH), 125.0 (C), 131.3 (CH), 140.8 (C), 170.2 (C), 170.9 (C), 173.5 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]⁺ calcd for C₁₅H₁₅N₃O₄Na 324.0960, found 324.0961; R_f (AcOEt) 0.67; mp 66-70 °C.

N-(2-(2-(Cyanomethyl)-3,10-dioxo-1,4-oxazecan-2-yl)phenyl)-acetamide (**2p**). Starting from Boc derivative **4j** (197.3 mg, 0.445 mmol), the general procedure afforded lactam **2p** as an amorphous solid (127.6 mg, yield 84%): 1 H NMR (300 MHz, DMSO- 1 d₆) δ 1.21–1.47 (m, 6H), 1.77 (s, 3H), 2.35 (m, 2H), 2.98 (m, 2H), 3.28 (s, 2H), 6.90 (d, 1 d = 8 Hz, 1H), 7.06 (t, 1 d = 8 Hz, 1H), 7.30–7.35 (m, 2H), 7.77 (s, 1H), 10.86 (s, 1H); 1 H NMR (300 MHz, CDCl₃) δ 1.18–1.53 (m,

6H), 1.89 (s, 3H), 2.30 (m, 2H), 2.64, 2.99 (ABq, J_{AB} = 17.5 Hz, 2H), 3.13 (m, 2H), 6.10 (br s, 1H), 6.86 (d, J = 8 Hz, 1H), 7.01 (t, J = 8 Hz, 1H), 7.24 (t, J = 8 Hz, 1H), 7.37 (d, J = 8 Hz, 1H), 9.38 (s, 1H); 13 C NMR (75.5 MHz, CDCl₃) δ 23.1 (CH₃), 24.2 (CH₂), 25.8 (CH₂), 26.2 (CH₂), 28.7 (CH₂), 33.3 (CH₂), 39.2 (CH₂), 75.3 (C), 111.1 (CH), 114.8 (C), 123.2 (CH), 123.3 (CH), 125.3 (C), 131.0 (CH), 141.1 (C), 170.9 (C), 171.2 (C), 173.6 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]⁺ calcd for $C_{18}H_{21}N_3O_4Na$ 366.1430, found 366.1431; R_t (AcOEt) 0.10.

Benzyl (2-(2-(Cyanomethyl)-3,10-dioxo-1,4-oxazecan-2-yl)phenyl)carbamate (2q). Starting from Boc derivative 4k (134.7 mg, 0.251 mmol), the general procedure afforded lactam 2q as an amorphous solid (60 mg, yield 55%): ¹H NMR (300 MHz, DMSO-d₆) δ 1.21–1.49 (m, 6H), 2.32 (m, 2H), 2.92 (m, 2H), 3.28 (s, 2H), 5.00 (s, 2H), 6.89 (d, J = 7.8 Hz, 1H), 7.03 (t, J = 7.5 Hz, 1H), 7.23 (t, J = 7.5 Hz, 1H), 7.25 (t, J = 7.5 H 7.8 Hz, 1H), 7.29-7.38 (m, 7H), 10.86 (s, 1H); ¹H NMR (300 MHz, CDCl₂) δ (two rotamers 15/85) 1.18–1.54 (m, 6H), 2.31 (m, 2H), 2.55 (d, I = 16.8 Hz, 1H), 2.97–3.11 (m, 3H), 4.90 (br s, 0.85 H), 5.01-5.07 (br s, 2H), 5.21 (br s, 0.15 H), 6.80 (d, I = 7.8 Hz, 1H), 6.98 (t, J = 7.2 Hz, 1H), 7.19 - 7.27 (m, 6H), 7.38 (d, J = 7.2 Hz, 1H), 8.70 (s, 0.85 H), 8.82 (s, 0.15 H); 13 C NMR (75.5 MHz, CDCl₃) δ 24.2 (CH₂), 25.8 (CH₂), 26.1 (CH₂), 29.4 (CH₂), 33.3 (CH₂), 40.7 (CH₂), 66.6 (CH₂), 75.2 (C), 111.0 (CH), 114.7 (C), 123.4 (CH), 125.2 (C), 128.1 (CH), 131.1 (CH), 136.6 (C), 140.7 (C), 156.5 (C), 171.1 (C), 173.7 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]⁺ calcd for C24H25N3O5Na 458.1692, found 458.1690; Rf (AcOEt/ petroleum ether 2/3) 0.20.

N-(2-(8-Methyl-6,9-dioxo-1,4,7-trioxa-10-azacyclododecan-8-yl)phenyl)acetamide (2r). Starting from Boc derivative 4m (82.8 mg, 0.184 mmol), the general procedure afforded lactam 2r as an amorphous solid (39.3 mg, yield 61%): ¹H NMR (300 MHz, DMSO- d_6) δ 1.50 (s, 3H), 1.78 (s, 3H), 3.14 (m, 2H), 3.30–3.49 (m, 6H), 4.17 (s, 2H), 6.86 (d, J = 7.5 Hz, 1H), 6.93 (t, J = 7.5 Hz, 1H), 7.22-7.26 (m, 2H), 7.87 (s, 1H), 10.62 (s, 1H); ¹H NMR (300 MHz, CDCl₃) δ 1.57 (s, 3H), 1.78 (s, 3H), 3.28–3.53 (m, 8H), 4.10, 4.13 (ABq, $J_{AB} = 16.8$ Hz, 2H), 6.45 (br s, 1H), 6.82 (d, J = 7.5 Hz, 1H), 6.96 (t, J = 7.5 Hz, 1H), 7.22-7.26 (m, 2H), 9.03 (s, 1H); 13 C NMR (75.5 MHz, CDCl₃) δ 23.0 (CH₃), 23.2 (CH₃), 39.2 (CH₂), 68.0 (CH₂), 69.7 (CH₂), 69.8 (CH₂), 70.9 (CH₂), 78.3 (C), 110.7 (CH), 122.4 (CH), 122.7 (CH), 129.0 (C), 129.9 (CH), 140.8 (C), 168.8 (C), 170.8 (C), 176.5 (C); HRMS (ESI, MeOH) m/z [M + Na] calcd for C₁₇H₂₂N₂O₆Na 373.1376, found 373.1379; R_f (AcOEt/ MeOH 9/1) 0.25.

rel-N-(2-((7S,8R)-2,6-Dioxo-7,8-diphenyl-1,5-diazonan-7-yl)phenyl)acetamide (2s). To a solution of Boc derivative 4o (32.0 mg, 0.059 mmol) in AcOEt (0.2 mL) was added a 3 M solution of anhydrous HCl in AcOEt (61 µL, 0.18 mmol). The mixture was stirred at room temperature for 1 h. The solvent was removed in vacuo. To the resulting solid were added CH2Cl2 (0.6 mL) and diisopropylethylamine (20 μ L, 0.11 mmol). The mixture was stirred overnight at room temperature and then diluted with ether (2 mL). The precipitate was collected on a sintered glass funnel, washed with ether (1 mL), and chromatographed over silica gel (2.2 g, eluent AcOEt) to afford compound 2s (19.4 mg, 77% yield) as a white solid: ¹H NMR (300 MHz, CDCl₃) δ 1.80 (s, 3H), 1.92–2.09 (m, 2H), 3.25, 3.29 (ABq, $J_{AB} = 6$ Hz, 2H), 3.77 (t, J = 6 Hz, 2H), 4.10 (t, J = 7.5 Hz, 1H), 5.56 (t, J = 5.7 Hz, 1H), 6.06 (br s, 1H), 6.56 (d, J = 7.2 Hz, 1H), 6.84-7.04 (m, 7H), 7.13-7.32 (m, 5H), 7.50 (br s 1H), 7.57-7.60 (m, 2H); 13 C NMR (75.5 MHz, CD₃OD) δ 22.5 (CH₃), 36.5 (CH₂), 37.0 (CH₂), 40.1 (CH₂), 52.0 (CH), 62.2 (C), 110.8 (CH), 123.0 (CH), 126.3 (CH), 128.0 (CH), 128.3 (CH), 128.4 (CH), 128.6 (CH), 128.9 (CH), 129.8 (CH), 131.0 (CH), 134.1(C), 138.2 (C), 140.7 (C), 141.9 (C), 173.2 (C), 173.6 (C), 181.5 (C); HRMS (ESI-TOF, MeOH) $m/z [M + Na]^+$ calcd for $C_{27}H_{27}N_3O_3Na$ 464.1950, found 464.1950; R_f (AcOEt/MeOH 9/1) 0.52; mp 191-197 °C.

Procedures for the Synthesis of Compounds 3 and 6. Nitroethylene, 20 and compounds $3d^{12e,f}$ and 6a (dr >20/1) 12e,c were prepared according to the literature. Nonracemic compounds $3e^{12c}$ and $3f^{12b}$ were previously described.

3-(2-Nitroethyl)-3-phenylindolin-2-one (6b). To a solution of oxindole 5a (1.00 g, 4.78 mmol) and triethylamine (60 μ L, 0.48 mmol) in dry CH₂Cl₂ (28 mL) at 0 °C and under argon atmosphere was added using a syringe pump (1.5 mL per hour) a solution of nitroethylene (0.65 mL, 9.57 mmol) in dry CH₂Cl₂ (20 mL). The resulting mixture was stirred overnight at 0 °C and then concentrated in vacuo. After purification by chromatography over silica gel (54.5 g, eluent CH2Cl2), the nitro compound 6b was afforded as a beige solid (1.03 g, 82% yield): 1 H NMR (300 MHz, CDCl₃) δ 2.82–2.92 (m, 1H), 3.02-3.11 (m, 1H), 4.09-4.30 (m, 2H), 6.92 (d, J = 7.5 Hz, 1H), 7.04 (td, J = 7.5, 1.2 Hz, 1H), 7.12–7.32 (m, 7H), 9.09 (broad s, 1H); 13 C NMR (75.5 MHz, CDCl₃) δ 33.8 (CH₂), 54.6 (C), 71.4 (CH₂), 110.8 (CH), 123.3 (CH), 124.8 (CH), 126.5 (CH), 128.0 (CH), 129.0 (CH), 129.1 (CH), 130.8 (C), 138.0 (C), 140.5 (C), 179.7 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]⁺ calcd for C₁₆H₁₄N₂O₃Na 305.0902, found 305.0899; R₆ (AcOEt/petroleum ether 1/1) 0.67; mp 114-116 °C.

3-Methyl-3-(2-nitroethyl)indolin-2-one (6c). Similarly, compound 6c (192 mg, 85%) was obtained from 5b: 1 H NMR (300 MHz, CDCl₃) δ 1.49 (s, 3H), 2.50–2.71 (m, 2H), 4.09–4.18 (m, 1H), 4.26–4.36 (m, 1H), 7.00 (d, J = 7.8 Hz, 1H), 7.11 (t, J = 7.3 Hz, 1H), 7.21–7.31 (m, 2H), 9.15 (broad s, 1H); 13 C NMR (75.5 MHz, CDCl₃) δ 23.8 (CH₃), 34.5 (CH₂), 46.8 (C), 71.5 (CH₂), 110.7 (CH), 123.1 (CH), 123.3 (CH), 128.9 (CH), 132.2 (C), 140.2 (C), 181.8 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]⁺ calcd for C₁₁H₁₂N₂O₃Na 243.0745, found 243.0745; R_f (AcOEt/petroleum ether 1/1) 0.47; mp 94–98 °C.

rel-(R)-3-((S)-2-Ñitro-1-phenylethyl)-3-phenylindolin-2-one (6d). Compound 6d was obtained according to the literature 12e and was recrystallized from a 3/2 2-propanol—water mixture: dr >25/1; 1 H NMR (300 MHz, CDCl₃) δ 4.73–4.78 (m, 2H), 3.02–3.11 (dd, J = 14.1, 12.3 Hz, 1H), 6.66 (d, J = 8.1 Hz, 1H), 7.03–7.19 (m, 7H), 7.28–7.47 (m, 4H), 7.69 (d, J = 6.0 Hz, 2H), 8.86 (s, 1H); 13 C NMR (75.5 MHz, CDCl₃) δ 50.2 (CH), 60.5 (C), 75.6 (CH₂), 110.1 (CH), 122.8 (CH), 124.8 (CH), 126.6 (CH), 128.07 (CH), 128.10 (CH), 128.15 (CH), 128.5 (CH), 129.0 (CH), 129.6 (CH), 131.6 (C), 133.9 (C), 137.8 (C), 139.4 (C), 179.2 (C); HRMS (ESI-TOF, MeOH/CH₂Cl₂) m/z [M + Na]⁺ calcd for C₂₂H₁₈N₂O₃Na 381.1215, found 381.1215; R_f (AcOEt/petroleum ether 1/1) 0.64; mp 204–211 °C.

rel-(S)-1-Acetyl-3-((S)-2-nitro-1-phenylethyl)-3-phenylindolin-2one (3a). To a solution of oxindole 6a (248 mg, 0.694 mmol), DMAP (8.5 mg, 0.069 mmol), and triethylamine (110 μ L, 0.76 mmol) in dry CH_2Cl_2 (1 mL) at 0 °C was added acetyl chloride (54 μ L, 0.76 mmol). The mixture was stirred at room temperature overnight and then washed with 10% aqueous citric acid. After aqueous workup, the resulting product was chromatographed over silica gel (8.2 g, eluent CH₂Cl₂) to afford nitro compound 3a as a white solid (243 mg, 88% yield): ${}^{1}H$ NMR (300 MHz, CDCl₃) δ 2.31 (s, 3H), 4.75–5.04 (m, 3H), 6.80 (d, I = 7.5 Hz, 2H), 7.07-7.21 (m, 3H), 7.39-7.52 (m, 6H), 7.63–7.66 (m, 2H), 8.11 (dd, J = 7.5, 1.8 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 26.3 (CH₃), 50.9 (CH), 60.2 (C), 76.0 (CH₂), 117.2 (CH), 125.1 (CH), 125.6 (CH), 126.5 (C), 127.8 (CH), 128.3 (CH), 128.8 (CH), 128.8 (CH), 128.9 (CH), 129.4 (CH), 129.9 (CH), 132.8 (C), 135.3 (C), 141.2 (C), 170.3 (C), 176.6 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]⁺ calcd for $C_{24}H_{20}N_2O_4Na$ 423.1321, found 423.1320; R_f (CH₂Cl₂) 0.68; mp 195–200 °C; IR 1746, 1710, 1554 cm⁻¹

1-Acetyl-3-(2-nitroethyl)-3-phenylindolin-2-one (**3b**). To a solution of oxindole **6b** (158.1 mg, 0.560 mmol), DMAP (6.84 mg, 0.056 mmol), and triethylamine (80 μ L, 0.62 mmol) in dry CH₂Cl₂ (0.7 mL) at 0 °C was added a solution of acetyl chloride (80 μ L, 1.12 mmol) in dry CH₂Cl₂ (0.7 mL). The mixture was stirred at room temperature for 5 h and then washed by 10% aqueous citric acid. After aqueous workup, the resulting product was dissolved in CH₂Cl₂ (2 mL) and treated with pentane (5 mL). The filtrate was concentrated in vacuo to give nitro compound **3b** as a white solid (126 mg, 70% yield): ¹H NMR (300 MHz, CDCl₃) δ 2.59 (s, 3H), 2.82–2.92 (m, 1H), 3.11–3.21 (m, 1H), 4.05–4.25 (m, 2H), 7.18–7.40 (m, 8H), 8.27 (d, J = 8.1 Hz, 1H). ¹³C NMR (75.5 MHz, CDCl₃) δ 26.6 (CH₃), 34.4 (CH₂), 54.6 (C), 71.4 (CH₂), 117.3 (CH), 124.4 (CH), 125.8 (CH),

126.5 (CH), 128.4 (CH), 128.8 (C), 129.1 (CH), 129.6 (CH), 137.8 (C), 140.0 (C), 170.7 (C), 177.9 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]⁺ calcd for C₁₈H₁₆N₂O₄Na 347.1008, found 347.1010; R_f (AcOEt/petroleum ether 1/1) 0.72; mp 147–150 °C.

1-Acetyl-3-methyl-3-(2-nitroethyl)indolin-2-one (3c). To a solution of oxindole 6c (97.2 mg, 0.441 mmol), DMAP (5.66 mg, 0.046 mmol), and triethylamine (72 μ L, 0.51 mmol) in dry CH₂Cl₂ (2 mL) at 0 °C was added acetyl chloride (35 µL, 0.48 mmol). The mixture was stirred at room temperature overnight and then diluted with CH2Cl2, washed with 10% aqueous citric acid, and dried over magnesium sulfate. After concentration in vacuo and purification by chromatography over silica gel (10 g, eluent CH₂Cl₂/petroleum ether 4/1), oxindole 3c was afforded as a white amorphous solid (84.3 mg, 73% yield): ¹H NMR (300 MHz, CDCl₃) δ 1.48 (s, 3H), 2.46–2.57 (m, 1H), 2.64–2.67 (m, 4H), 4.10–4.29 (m, 2H), 7.23–7.29 (m, 2H), 7.31–7.39 (m, 1H), 8.23 (d, J = 8.1 Hz, 1H); ¹³C NMR (75.5 MHz, $CDCl_3$) δ 24.6 (CH₃), 26.5 (CH₃), 35.0 (CH₂), 46.6 (C), 71.0 (CH₂), 116.9 (CH), 122.2 (CH), 125.7 (CH), 129.1 (CH), 130.7 (C), 139.1 (C), 170.7 (C), 179.8 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]+ calcd for C₁₃H₁₄N₂O₄Na 285.0851, found 285.0852; R_f (CH₂Cl₂) 0.37.

tert-Butyl 3-(2-Nitroethyl)-2-oxo-3-phenylindoline-1-carboxylate (3e). To a solution of oxindole 6b (142.2 mg, 0.500 mmol) and DMAP (5.66 mg, 0.046 mmol) in dry CH₂Cl₂ (8 mL) at 0 °C was added tert-butyl pyrocarbonate (120 mg, 0.55 mmol). The mixture was stirred at room temperature for 2.5 h and then diluted with CH₂Cl₂ washed with 10% aqueous citric acid, and dried over magnesium sulfate. After concentration in vacuo and purification by chromatography over silica gel (10 g, eluent 1% triethylamine in CH2Cl2), oxindole 3e was afforded as a white solid (96.3 mg, 53% yield): ¹H NMR (300 MHz, CDCl₃) δ 1.49 (s, 9H), 2.80–2.90 (m, 1H), 3.08– 3.18 (m, 1H), 4.05-4.15 (m, 1H), 4.20-4.30 (m, 1H), 7.19-7.38 (m, 8H), 7.88 (d, I = 8.1 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 28.0 (CH₃), 34.6 (CH₂), 54.4 (C), 71.4 (CH₂), 85.1 (C), 115.7 (CH), 124.6 (CH), 125.1 (CH), 126.7 (CH), 128.3 (CH), 128.7 (C), 129.1 (CH), 129.5 (CH), 138.0 (C), 139.6 (C), 148.9 (C), 175.4 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]⁺ calcd for $C_{21}H_{22}N_2O_5Na$ 405.1426, found 405.1425; R_f (AcOEt/petroleum ether 1/6) 0.80; mp

tert-Butyl 3-Methyl-3-(2-nitroethyl)-2-oxoindoline-1-carboxylate (3f). Similarly, compound 3f (733 mg, 64% yield) was obtained as a white solid from 6c: 1 H NMR (300 MHz, CDCl₃) δ 1.19 (s, 3H), 1.59 (s, 9H), 2.38–2.48 (m, 1H), 2.55–2.64 (m, 1H), 4.00–4.10 (m, 1H), 4.18–4.28 (m, 1H), 7.14–7.20 (m, 2H), 7.28–7.32 (m, 1H), 7.80 (d, J = 8.1 Hz, 1H); 13 C NMR (75.5 MHz, CDCl₃) δ 24.3 (CH₃), 27.8 (CH₃), 34.8 (CH₂), 46.3 (C), 70.9 (CH₂), 84.6 (C), 115.2 (CH), 122.3 (CH), 124.8 (CH), 128.7 (CH), 130.4 (C), 138. Six (C), 148.7 (C), 177.3 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]⁺ calcd for C₁₆H₂₀N₂O₃Na 343.1270, found 343.1266; R_f (CH₂Cl₂) 0.33; mp 106–109 °C.

(S)-1-(Methylsulfonyl)-3-((S)-2-nitro-1-phenylethyl)-3-phenylindolin-2-one (3g). To a solution of oxindole 6a (121.4 mg, 0.339 mmol), DMAP (4.70 mg, 0.038 mmol), and triethylamine (56 μ L, 0.40 mmol) in dry $\mathrm{CH_2Cl_2}$ (2 mL) at 0 °C was added methanesulfonyl chloride (30 μ L, 0.39 mmol). The mixture was stirred at room temperature overnight. After aqueous workup, the resulting product was chromatographed over silica gel (22 g, eluent CH2Cl2) to afford nitro compound 3g as a white solid (78 mg, 53% yield): 1H NMR $(300 \text{ MHz}, \text{CDCl}_3) \delta 2.54 \text{ (s, 3H)}, 4.73-4.99 \text{ (m, 3H)}, 6.79-6.81 \text{ (m, starting of the content of the content$ 2H), 7.10-7.21 (m, 3H), 7.40-7.53 (m, 6H), 7.60-7.64 (m, 2H), 7.72 (d, J = 7.5 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 40.1 (CH₃), 51.2 (CH), 59.7 (C), 76.3 (CH₂), 114.2 (CH), 125.0 (CH), 126.0 (C), 126.4 (CH), 127.6 (CH), 128.5 (CH), 128.8 (CH), 129.1 (CH), 129.4 (CH), 129.5 (CH), 130.3 (CH), 133.4 (C), 134.3 (C), 140.1 (C), 174.4 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]⁺ calcd for C₂₃H₂₀N₂O₅SNa 459.0991, found 459.0993; R_f (CH₂Cl₂) 0.74; mp dec 160 °C.

Synthesis of Compound 7. A mixture of nitro compound 3a (42.25 mg, 0.105 mmol) and 10% Pd on C (30.3 mg) in MeOH (2 mL) was stirred at room temperature under an H₂ balloon overnight.

After filtration through a pad of Celite, concentration in vacuo, and purification by chromatography over silica gel (2g, eluent 80/20 CH₂Cl₂/AcOEt), hydroxamic acid 7 (30.0 mg, yield 74%) and lactam **2a** (5.80 mg, yield 15%) were afforded as white amorphous solids: $^1\mathrm{H}$ NMR (300 MHz, DMSO- d_6) 1.24 (s, 3H), 3.79 (dd, J=9.9, 4.5 Hz, 1H), 4.11 (dd, J=9.9, 6.6 Hz, 1H), 4.63 (dd, J=6 Hz, J=4.5 Hz, 1H), 6.57 (m, 2H), 6.81–6.84 (m, 2H), 6.96–7.00 (m, 6 H), 7.37 (m, 2 H), 7.51 (dd, J=7.8, 1.8 Hz, 1H), 8.09 (d, J=7.5 Hz, 1H), 10.00 (s, 1H),10.64 (br s, 1H); $^{13}\mathrm{C}$ NMR (75.5 MHz, CD₃OD) δ 23.1 (CH₃), 46.3 (CH), 54.3 (CH₂), 62.4 (C), 126.6 (CH), 127.8 (CH), 128.1 (CH), 128.4 (CH), 128.9 (CH), 129.1 (CH), 129.4 (CH), 129.4 (CH), 140.9 (C), 170.5 (C), 173.0 (C); HRMS (ESI-TOF, CH₃OH) m/z [M + Na] $^+$ calcd for C₂₄H₂₂N₂O₃Na 409.1523, found 409.1521; $R_f=0.08$ (AcOEt).

Procedures for the Synthesis of Compounds 8. Compound 8d was prepared according to the literature. ¹⁶

1-Acetyl-3-hydroxy-3-methylindolin-2-one (8a). Under argon atmosphere, a 2.5 M solution of methylmagnesium bromide in ether (2.8 mL, 7 mmol) was added using a syringe pump (0.5 mL per hour) to a mixture of acetylisatin (1.23 g, 6.53 mmol) and THF (33 mL) at -60 °C. The resulting mixture was stirred overnight at −60 °C, quenched with 1 M chlorhydric acid (8 mL) at −60 °C, and then concentrated in vacuo. The aqueous phase was extracted with AcOEt (3 × 8 mL). The organic phase was dried over sodium sulfate, concentrated in vacuo, and purified by chromatography over silica gel (42 g, eluent CH₂Cl₂). Hydroxyoxindole 8a was afforded as a pale yellow solid (0.528 g, 45% yield): 1 H NMR (300 MHz, CDCl₃) δ 1.67 (s, 3H), 2.70 (s, 3H), 3.15 (broad s, 1H), 7.17 (td, J = 7.5, 1.2 Hz, 1H), 7.29 (td, *J* = 7.9, 1.5 Hz, 1H), 7.37 (dd, *J* = 7.5, 1.2 Hz, 1H), 8.11 (d, J = 7.9 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 25.6 (CH₃), 26.4 (CH₃), 73.6 (C), 116.9 (CH), 123.2 (CH), 125.8 (CH), 130.1 (CH), 130.5 (C), 139.0 (C), 170.9 (C), 179.1 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]⁺ calcd for $C_{11}H_{11}NO_3Na$ 228.0636, found 228.0643; R_f (AcOEt) 0.77; mp 119–121 °C (lit.²¹ mp 102–103 °C).

1-Acetyl-5-fluoro-3-hydroxy-3-methylindolin-2-one (8b). Similarly, compound 8b (0.155 g, 21% yield) was afforded as a light yellow solid from 1-acetyl-5-fluoroisatin (0.677 g, 3.27 mmol) and 2.5 M MeMgBr in ether (1.7 mL, 4.2 mmol): 1 H NMR (300 MHz, CDCl₃) δ 1.65 (s, 3H), 2.66 (s, 3H), 3.15 (s, 1H), 7.08 (td, J = 9, 2.7 Hz, 1H), 7.18 (dd, J = 7.5, 2.7 Hz, 1H), 8.22 (dd, J = 9, 4.5 Hz, 1H); 13 C NMR (75.5 MHz, CDCl₃) δ 25.7 (CH₃), 26.4 (CH₃), 73.6 (d, J = 1.7 Hz, C), 110.8 (d, J = 24.4 Hz, CH), 116.6 (d, J = 22.7 Hz, CH), 118.5 (d, J = 7.8 Hz, CH), 132.3 (d, J = 7.9 Hz, C), 134.9 (d, J = 2.6 Hz, C), 160.6 (d, J = 246 Hz, C), 170.6 (C), 178.8 (C); HRMS (ESITOF, MeOH) m/z [M – H]⁻ calcd for C₁₁H₉NO₃F 222.0572, found 222.0570; R_f (AcOEt/petroleum ether 1/1) 0.56; mp 112–116 °C.

1-Acetyl-3-hydroxy-5-methoxy-3-methylindolin-2-one (8c). Similarly, compound 8c (0.345 g, 29% yield) was afforded as a light yellow solid from 1-acetyl-5-methoxyisatin (1.117 g, 5.09 mmol) and 2.5 M MeMgBr in ether (2.50 mL, 6.2 mmol): 1 H NMR (300 MHz, CDCl₃) δ 1.53 (s, 3H), 2.49 (s, 3H), 3.53 (s, 1H), 3.73 (s, 3H), 6.77 (dd, J = 8.7, 2.7 Hz, 1H), 6.89 (d, J = 2.7 Hz, 1H), 8.00 (d, J = 8.7 Hz, 1H); 13 C NMR (75.5 MHz, CDCl₃) δ 25.6 (CH₃), 26.2 (CH₃), 55.6 (CH₃), 73.7 (C), 109.0 (CH), 114.9 (CH), 118.0 (CH), 131.9 (C), 132.2 (C), 157.7 (C), 170.7 (C), 179.2 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]+ calcd for C₁₂H₁₃NO₄Na 258.0742, found 258.0741; R_f (AcOEt/petroleum ether 1/1) 0.63; mp 118–120 °C.

Benzyl 3-Hydroxy-3-(cyanomethyl)-2-oxoindoline-1-carboxylate (8e). A mixture of N-benzyloxycarbonyl isatin²² (0.485 g, 1.73 mmol), cyanoacetic acid (0.170 g, 2.00 mmol), and triethylamine (0.050 mL, 0.10 mmol) in DMF (8.5 mL) was heated at 70 °C for 3 h. DMF was removed in vacuo. Water was added and extracted three times with diethyl ether. After drying of the organic phases over sodium sulfate and concentration in vacuo, purification by chromatography over silica gel (16 g, eluent DCM) gave product 8e as a beige solid (0.305 g, 54% yield): ¹H NMR (300 MHz, CDCl₃) δ 2.65, 2.95 (ABq, J_{AB} = 18 Hz, 2H), 3.59 (br s, 1H), 5.34 (m, 2H), 7.18–7.39 (m, 7H), 7.58 (dd, J = 7.5, 1 Hz, 1H), 7.84 (d, J = 8.1 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 27.9 (CH₂), 69.3 (CH₂), 72.3 (C), 114.8 (C), 115.8 (CH),

124.2 (CH), 125.9 (CH), 126.3 (C), 128.4 (CH), 128.7 (CH), 128.8 (CH), 131.4 (CH), 134.3 (C), 138.5 (C), 150.1 (C), 173.7 (C); HRMS (ESI-TOF, acetone) m/z [M + Na]⁺ calcd for C₁₈H₁₄N₂O₄Na 345.0851, found 345.0849; R_f (AcOEt/DCM 1/9) 0.42; mp 59–68 °C.

3-Hydroxy-3-(cyanomethyl)-N,N-dimethyl-2-oxoindoline-1-carboxamide (8f). A mixture of N-dimethylcarbamoyl isatin²³ (0.472 g, 2.17 mmol), cyanoacetic acid (0.213 g, 2.39 mmol), and triethylamine (0.060 mL, 0.43 mmol) in DMF (11 mL) was heated at 70 °C for 3 h. DMF was removed in vacuo. Water was added and extracted three times with diethyl ether. After drying of the organic phases over sodium sulfate and concentration in vacuo, purification by chromatography over silica gel (11 g, eluent DCM) gave product 8f as a beige solid (0.405 g, 72% yield): ¹H NMR (300 MHz, DMSO-d₆) δ 2.98 (s, 3H), 3.05 (s, 3H), 3.20 (s, 2H), 6.97 (s, 1H), 7.09 (d, J = 7.8Hz, 1H), 7.21 (td, I = 7.8, 1.2 Hz, 1H), 7.40 (td, I = 7.8, 1.2 Hz, 1H), 7.57 (d, I = 7.2 Hz, 1H). ¹H NMR (300 MHz, CDCl₃) δ 2.84–3.18 (m, 8H), 3.66 (br s, 1H), 7.16 (d, J = 8.1 Hz, 1H), 7.22 (td, J = 7.8, 1.2)Hz, 1H), 7.40 (td, J = 7.8, 1.2 Hz, 1H), 7.58 (d, J = 8 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 27.20 (CH₂), 36.87 (CH₃), 38.41 (CH₃), 73.24 (C), 113.28 (CH), 115.05 (C), 123.94 (CH), 124.79 (CH), 127.37 (C), 131.06 (CH), 139.75 (C), 150.89 (C), 173.58 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]⁺ calcd for $C_{13}H_{13}N_3O_3Na$ 282.0855, found 282.0858; R_f (AcOEt) 0.55; mp 132-139 °C.

General Procedure for the Synthesis of Compounds 4. To a solution of 3-hydroxyoxindole 8a (205.5 mg, 1.00 mmol) in CH₂Cl₂ (1 mL) were successively added Boc- β -alanine (227 mg, 1.2 mmol), DCC (227 mg, 1.1 mmol), and DMAP (147 mg, 1.2 mmol). The resulting mixture was stirred for 5 h at room temperature and then diluted with CH₂Cl₂ (10 mL) and filtered. The filtrate was successively washed with aqueous 10% citric acid, aqueous 10% sodium carbonate, and water. After drying over magnesium sulfate and concentration in vacuo, the residue was chromatographed over silica gel (11 g, eluant: 1% Et₃N in CH₂Cl₂) to yield Boc derivative 4b (359 mg) as an amorphous solid: yield 95%.

1-Acetyl-3-methyl-2-oxoindolin-3-yl (tert-Butoxycarbonyl)-glycinate (4a). According to the general procedure, 4a was obtained as a viscous liquid (132 mg, yield: 69%) from 3-hydroxyoxindole 8a (108 mg, 0.526 mmol), Boc-Gly-OH (101.4 mg, 0.579 mmol), DCC (119.5 mg, 0.579 mmol), and DMAP (77.1 mg, 0.631 mmol): 1 H NMR (300 MHz, CDCl₃) δ 1.33 (s, 9H), 1.61 (s, 3H), 2.62 (s, 3H), 3.91 (d, J = 6 Hz, 2H), 4.77 (br s, 1H), 7.20–7.26 (m, 2H), 7.32 (t, J = 6 Hz, 1H), 8.19 (d, J = 6 Hz, 1H); 13 C NMR (75.5 MHz, CDCl₃) δ 23.8 (CH₃), 26.5 (CH₃), 28.2 (CH₃), 42.0 (CH₂), 77.9 (C), 80.1 (C), 116.8 (CH), 122.1 (CH), 125.6 (C), 130.4 (CH), 139.5 (C), 155.3 (C), 168.9 (C), 170. Seven (C), 175.0 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]⁺ calcd for C₁₈H₂₂N₂O₆Na 385.1376, found 385.1375; R_f (AcOEt/petroleum ether) 0.38.

1-Acetyl-3-methyl-2-oxoindolin-3-yl 3-((tert-butoxycarbonyl)-amino)propanoate (4b): ¹H NMR (300 MHz, CDCl₃) δ 1.35 (s, 9H), 1.59 (s, 3H), 2.50 (m, 2H), 2.62 (s, 3H), 3.25 (m, 2H), 4.77 (br s, 1H), 7.12–7.22 (m, 2H), 7.31 (t, J = 7.8 Hz, 1H), 8.19 (d, J = 8.1 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 23.9 (CH₃), 26.5 (CH₃), 28.4 (CH₃), 34.1 (CH₂), 36.0 (CH₂), 77.3 (C), 79.5 (C), 116.8 (CH), 121.8 (CH), 125.5 (CH), 128.1 (C), 130.2 (CH), 139.5 (C), 155.7 (C), 170.7 (C), 170. Nine (C), 175.4 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]+ calcd for C₁₉H₂₄N₂O₆Na 399.1532, found 399.1532; R_f (AcOEt/petroleum ether 1/1) 0.77.

1-Acetyl-3-methyl-2-oxoindolin-3-yl 4-((tert-Butoxycarbonyl)-amino)butanoate (4c). According to the general procedure, 4c was obtained as a viscous oil (210 mg, yield: 78%) from 3-hydroxyoxindole 8a (142.0 mg, 0.692 mmol), Boc-NH-(CH₂)₃-COOH (168.6 mg, 0.830 mmol), DCC (157.5 mg, 0.761 mmol), and DMAP (101.2 mg, 0.830 mmol): 1 H NMR (300 MHz, CDCl₃) δ 1.34 (s, 9H), 1.56 (s, 3H), 1.62 (m, 2H), 2.29 (m, 2H), 2.58 (s, 3H), 3.00 (m, 2H), 4.75 (br s, 1H), 7.12 (t, J = 6.8 Hz, 1H), 7.19–7.27 (m, 2H), 8.16 (d, J = 8.4 Hz, 1H); 13 C NMR (75.5 MHz, CDCl₃) δ 23.7 (CH₃), 24.9 (CH₂), 26.3 (CH₃), 28.2 (CH₃), 30.6 (CH₂), 39.3 (CH₂), 76.8 (C), 78.9 (C), 116.5 (CH), 121.6 (CH), 125.3 (CH), 128.1 (C), 129.9 (CH), 139.3 (C), 155.8 (C), 170.5 (C), 171.4 (C), 175.3 (C); HRMS (ESI-TOF,

MeOH) m/z [M + Na]⁺ calcd for $C_{20}H_{26}N_2O_6Na$ 413.1688, found 413.1689; R_f (AcOEt/CH₂Cl₂ 1/4): 0.71.

1-Acetyl-3-methyl-2-oxoindolin-3-yl 5-((tert-butoxycarbonyl)-amino)pentanoate (4d). According to the general procedure, 4d was obtained as a white solid (251 mg, yield: 95%) from 3-hydroxyoxindole 8a (134.8 mg, 0.656 mmol), Boc-NH-(CH₂)₄-COOH (170.9 mg, 0.787 mmol), DCC (148.8 mg, 0.721 mmol), and DMAP (96.1 mg, 0.787 mmol): 1 H NMR (300 MHz, CDCl₃) δ 1.36–1.42 (m, 11H), 1.47–1.58 (m, 5H), 2.29 (m, 2H), 2.62 (s, 3H), 3.01 (m, 2H), 4.46 (br s, 1H), 7.11–7.21 (m, 2H), 7.28 (td, J = 7.8, 1.8 Hz, 1H), 8.19 (d, J = 8.4 Hz, 1H); 13 C NMR (75.5 MHz, CDCl₃) δ 21.8 (CH₃), 23.9 (CH₂), 26.5 (CH₃), 28.4 (CH₃), 29.2 (CH₂), 33.0 (CH₂), 39.9 (CH₂), 76.9 (C), 79.2 (C), 116.8 (CH), 121.7 (CH), 125.4 (CH), 128.3 (C), 130.1 (CH), 139.5 (C), 155.9 (C), 170.8 (C), 171.8 (C), 175.6 (C); HRMS (ESI, MeOH) m/z [M + Na]⁺ calcd for C₂₁H₂₈N₂O₆Na 427.1845, found 427.1844; R_f (AcOEt/CH₂Cl₂ 1/4) 0.78; mp 98–102 °C.

1-Acetyl-3-methyl-2-oxoindolin-3-yl 6-((tert-Butoxycarbonyl)-amino)hexanoate (4e). According to the general procedure, 4e was obtained as a solid (406.8 mg, yield: 97%) from 3-hydroxyoxindole 8a (199.5 mg, 0.972 mmol), Boc-NH-(CH₂)₅-COOH (269 mg, 1.170 mmol), DCC (221 mg, 1.07 mmol), and DMAP (143 mg, 1.17 mmol): 1 H NMR (300 MHz, CDCl₃) δ 1.16–1.26 (m, 2H), 1.32–1.42 (m, 2H), 1.36 (s, 9H), 1.44–1.56 (m, 2H), 1.58 (s, 3H), 2.26 (m, 2H), 2.62 (s, 3H), 3.00 (m, 2H), 4.48 (br s, 1H), 7.11–7.26 (m, 2H), 7.29 (t, J = 7.6 Hz, 1H), 8.19 (d, J = 8.4 Hz, 1H); 13 C NMR (75.5 MHz, CDCl₃) δ 23.8 (CH₃), 24.3 (CH₂), 26.0 (CH₂), 26.5 (CH₃), 28.4 (CH₃), 29.6 (CH₂), 33.9 (CH₂), 40.3 (CH₂), 76.9 (C), 79.0 (C), 116.8 (CH), 121.6 (CH), 125.4 (CH), 128.3 (C), 130.0 (CH), 139.5 (C), 155.9 (C), 170.7 (C), 171.9 (C), 175.5 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]⁺ calcd for C₂₂H₃₀N₂O₆Na 441.2001, found 441.1998; R_f (AcOEt/CH₂Cl₂ 1/9) 0.64; mp 67–72 °C.

1-Acetyl-5-fluoro-3-methyl-2-oxoindolin-3-yl 3-((tert-Butoxycarbonyl)amino)propanoate (4f). According to the general procedure, compound 4f was obtained as a pale yellow solid (140 mg, yield: 60%) from 3-hydroxyoxindole 8b (132 mg, 0.595 mmol), Boc-NH-(CH₂)₂-COOH (135 mg, 0.714 mmol), DCC (135 mg, 0.655 mmol), and DMAP (87.2 mg, 0.714 mmol): ¹H NMR (300 MHz, CDCl₃) δ 1.36 (s, 9H), 1.58 (s, 3H), 2.52 (t, J = 6 Hz, 2H), 2.61 (s, 3H), 3.25 (m, 2H), 4.75 (broad s, 1H), 6.92 (dd, *J* = 7.2, 2.7 Hz, 1H), 7.00 (td, J = 9, 2.7 Hz, 1H), 8.20 (dd, J = 9, 4.8 Hz, 1H); ¹³C NMR (75.5 MHz, CD₃OD) δ 23.9 (CH₃), 26.4 (CH₃), 28.7 (CH₃), 34.7 (CH_2) , 37.02 (CH_2) , 78.3 (d, J = 1.7 Hz, C), 80.3 (C), 110.9 (d, J = 25)Hz, CH), 117.2 (d, J = 23 Hz, CH), 119.2 (d, J = 7.8 Hz, CH), 132.0 (d, J = 8.2 Hz, C), 137.1 (d, J = 2.6 Hz, C), 158.2 (C), 161.8 (d, J = 2.6 Hz, C)244 Hz, C), 171.9 (C), 171.9 (C), 176.6 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]⁺ calcd for C₁₉H₂₃FN₂O₆Na 417.1438, found 417.1439; R_f (AcOEt/petroleum ether 1/1) 0.65; mp 118–121 °C.

1-Acetyl-5-methoxy-3-methyl-2-oxoindolin-3-yl 3-((tert-Butoxycarbonyl)amino)propanoate (4g). According to the general procedure, 4g was obtained as a solid (195.1 mg, yield: 91%) from hydroxyoxindole 8c (124.6 mg, 0.529 mmol), Boc-NH-(CH₂)₂-COOH (120.2 mg, 0.636 mmol), DCC (120 mg, 0.582 mmol), and DMAP (77 mg, 0.64 mmol): 1 H NMR (300 MHz, CDCl₃) δ 1.35 (s, 9H), 1.57 (s, 3H), 2.50 (m, 2H), 2.60 (s, 3H), 3.25 (m, 2H), 3.74 (s, 3H), 4.80 (br s, 1H), 6.74 (d, J = 2.4 Hz, 1H), 6.81 (dd, J = 8.7, 2.4 Hz, 1H), 8.13 (d, J = 8.7 Hz, 1H); 13 C NMR (75.5 MHz, CDCl₃) δ 24.0 (CH₃), 26.4 (CH₃), 28.3 (CH₃), 34.0 (CH₂), 36.0 (CH₂), 55.6 (CH₃), 77.3 (C), 79.5 (C), 108.2 (CH), 114.3 (CH), 117.9 (CH), 129.5 (C), 132.8 (C), 155.7 (C), 157.5 (C), 170.4 (C), 170.9 (C), 175.4 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]⁺ calcd for C₂₀H₂₆N₂O₇Na 429.1637, found 429.1635; R_f (AcOEt/CH₂Cl₂ 1/9) 0.67; mp 112–114 °C.

1-Acetyl-5-methoxy-3-methyl-2-oxoindolin-3-yl 6-((tert-Butoxycarbonyl)amino)hexanoate (4h). According to the general procedure, 4h was obtained as a solid (185.68 mg, yield: 78%) from hydroxyoxindole 8c (125.9 mg, 0.535 mmol), Boc-NH-(CH₂)₅-COOH (148.5 mg, 0.642 mmol), DCC (121.4 mg, 0.588 mmol), and DMAP (78.4 mg, 0.642 mmol): 1 H NMR (300 MHz, CDCl₃) δ 1.17–1.27 (m, 2H), 1.34–1.43 (m, 11 H), 1.46–1.50 (m, 5H), 2.18–

2.37 (m, 2H), 2.59 (s, 3H), 2.98–3.04 (m, 2H), 3.74 (s, 3H), 4.50 (broad s, 1H), 6.73 (d, J = 2.7 Hz, 1H),), 6.79 (dd, J = 9, 2.7 Hz, 1H), 8.12 (d, J = 9 Hz, 1H); 13 C NMR (75.5 MHz, CDCl₃) δ 23.9 (CH₃), 24.3 (CH₂), 26.0 (CH₃), 26.4 (CH₂), 28.4 (CH₃), 29.6 (CH₂), 33.4 (CH₂), 40.3 (CH₂), 55.6 (CH₃), 77.2 (C), 79.1 (C), 108.2 (CH), 114.1 (CH), 117.9 (CH), 129.8 (C), 132.9 (C), 156.0 (C), 157.4 (C), 170.5 (C), 171.9 (C), 175.6 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]⁺ calcd for C₂₃H₃₂N₂O₇Na 471.2107, found 471.2102; R_f (AcOEt/CH₂Cl₂ 1/9) 0.64; mp 109–112 °C.

1-Acetyl-3-(cyanomethyl)-2-oxoindolin-3-yl 3-((tert-Butoxycarbonyl)amino)propanoate (4i). According to the general procedure, 4i was obtained as a solid (110.5 mg, yield: 59%) from 3-hydroxyoxindole 8d (108 mg, 0.469 mmol), Boc-NH-(CH₂)₂-COOH (106 mg, 0.56 mmol), and DCC (106 mg, 0.516 mmol) after 5 days at 40 °C: ¹H NMR (300 MHz, CDCl₃) δ 1.35 (s, 9H), 2.57 (m, 2H), 2.62 (s, 3H), 2.74, 3.05 (ABq, J_{AB} = 16.5 Hz, 2H), 4.75 (br s, 1H), 7.23 (t, J = 8 Hz, 1H), 7.39–7.49 (m, 2H), 8.23 (d, J = 8 Hz, 1H); 13 C NMR (75.5 MHz, CDCl₃) δ 26.5 (CH₃), 26.7 (CH₂), 28.3 (CH₃), 34.0 (CH₂), 35.9 (CH₂), 75.1 (C), 79.7 (C), 113.8 (C), 117.2 (CH), 122.8 (CH), 123.7 (C), 126.1 (CH), 131.8 (CH), 140.0 (C), 155.6 (C), 170.2 (C), 172.4 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]+ calcd for C₂₀H₂₃N₃O₆Na 424.1485, found 424.1486; R_f (AcOEt) 0.71; mp 74–77 °C.

1-Acetyl-3-(cyanomethyl)-2-oxoindolin-3-yl 6-((tert-Butoxycarbonyl)amino)hexanoate (4j). According to the general procedure, 4j was obtained (222 mg, yield: 98%) as a vitreous solid from hydroxyoxindole 8d (117.8 mg, 0.511 mmol), Boc-NH-(CH₂)₆-COOH (142 mg, 0.614 mmol), and DCC (116 mg, 0.562 mmol) after 5 days at 40 °C: 1 H NMR (300 MHz, CDCl₃) δ 1.25 (m, 2H), 1.28–1.39 (m, 11 H), 1.53 (m, 2H), 2.32 (m, 2H), 2.61 (s, 3H), 2.72 (d, J = 17.5 Hz, 1H), 3.00–3.08 (m, 3H), 4.48 (br s, 1H), 7.23 (t, J = 8 Hz, 1H), 7.39–7.49 (m, 2H), 8.23 (d, J = 8 Hz, 1H); 13 C NMR (75.5 MHz, CDCl₃) δ 24.2 (CH₂), 25.9 (CH₂), 26.5 (CH₃), 26.7 (CH₂), 28.4 (CH₃), 29.6 (CH₂), 33.2 (CH₂), 40.2 (CH₂), 74.7 (C), 79.1 (C), 113.9 (C), 117.1 (CH), 122.7 (CH), 124.0 (C), 126.0 (CH), 131.6 (CH), 140.0 (C), 155.9 (C), 170.2 (C), 171.2 (C), 172.6 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]⁺ calcd for C₂₃H₂₉N₃O₆Na 466.1954, found 466.1953; R_f (AcOEt/petroleum ether 1/1) 0.60.

Benzyl 3-((6-((tert-Butoxycarbonyl)amino)hexanoyl)oxy)-3-(cyanomethyl)-2-oxoindoline-1-carboxylate (4k). According to the general procedure, 4k was obtained (153 mg, yield: 72%) after 3 days at 45 °C as an amorphous solid from hydroxyoxindole 8e (128.6 mg, 0.399 mmol), Boc-NH-(CH₂)₅-COOH (121.3 mg, 0.520 mmol), and DCC (92 mg, 0.45 mmol): 1 H NMR (300 MHz, CDCl₃) δ 1.15– 1.26 (m, 2H), 1.32–1.42 (m, 11H), 1.46–1.56 (m, 2H), 2.31 (m, 2H), 2.63 (d, J = 17.4 Hz, 1H), 2.96-3.08 (m, 3H), 4.48 (br s, 1H), 5.33, 5.39 (ABq, J_{AB} = 12.3 Hz, 2H), 7.19 (t, J = 7.7 Hz, 1H), 7.29–7.43 (m, 7H), 7.92 (d, J = 8.1 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 24.2 (CH₂), 25.9 (CH₂), 26.6 (CH₂), 28.4 (CH₃), 29.6 (CH₂), 33.2 (CH₂), 40.3 (CH₂), 69.1 (CH₂), 74.5 (C), 79.1 (C), 114.1 (C), 115.9 (CH), 123.0 (CH), 124.0 (C), 125.6 (CH), 128.2 (CH), 128.6 (CH), 128.7 (CH), 131.6 (CH), 134.6 (C), 139.3 (C), 150.1 (C), 156.0 (C), 170.0 (C), 171.1 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]⁺ calcd for $C_{29}H_{33}N_3O_7Na$ 558.2216, found 558.2221; R_f (AcOEt/CH₂Cl₂ 5/95) 0.53.

1-(Dimethylcarbamoyl)-3-(cyanomethyl)-2-oxoindolin-3-yl 6-((tert-Butoxycarbonyl)amino)hexanoate (4I). According to the general procedure, 4I was obtained as an amorphous solid (170 mg, yield: 73%) after 3 days at 45 °C from hydroxyoxindole 8f (127.1 mg, 0.49 mmol), Boc-NH-(CH₂)₅-COOH (138 mg, 0.60 mmol) and DCC (111 mg, 0.539 mmol): 1 H NMR (300 MHz, CDCl₃) δ 1.18–1.26 (m, 2H), 1.32–1.40 (m, 11H), 1.42–1.55 (m, 2H), 2.31 (m, 2H), 2.6–3.06 (m, 10H), 4.69 (br s, 1H), 7.08–7.15 (m, 2H), 7.33 (dd, J = 8, 1.5 Hz, 1H), 7.43 (d, J = 7.2 Hz, 1H); 13 C NMR (75.5 MHz, CDCl₃) δ 24.00 (CH₂), 25.67 (CH₂), 26.18 (CH₂), 28.17 (CH₃), 29.28 (CH₂), 33.07 (CH₂), 36.62 (CH₃), 37.88 (CH₃), 39.96 (CH₂), 74.77 (C), 78.70 (C), 112.95, 114.16 (C), 122.89, 124.09 (C), 124.29, 131.07, 139.82 (C), 150.31 (C), 155.74 (C), 169.20 (C), 170.92 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]+ calcd for C₂₄H₃₂N₄O₆Na 495.2219, found 495.2221; R_f (AcOEt/petroleum ether 1/1) 0.50.

1-Acetyl-3-methyl-2-oxoindolin-3-yl 8-(tert-Butoxycarbonyl)amino)-3,6-dioxaoctanoate (4m). According to the general procedure, 4m was obtained (59.1 mg, yield: 51%) as a viscous oil from hydroxyoxindole 8a (53 mg, 0.258 mmol), Boc-NH-(CH₂)₂O-(CH₂)₂OCH₂COOH 9a¹⁷ (0.284 mmol), DCC (70.8 mg, 0.343 mmol), and DMAP (31.5 mg, 0.258 mmol): ¹H NMR (300 MHz, CDCl₃) δ 1.36 (s, 9H), 1.61 (s, 3H), 2.61 (s, 3H), 3.22 (m, 2H), 3.42 $(t, J = 5 \text{ Hz}, 2\text{H}), 3.50-3.59 \text{ (m, 4H)}, 4.07, 4.14 \text{ (ABq, } J_{AB} = 17 \text{ Hz},$ 2H), 4.91 (br s, 1H), 7.14 (t, *J* = 7.5 Hz, 1H), 7.21 (d, *J* = 7.5 Hz, 1H), 7.31 (t, J = 7.8 Hz, 1H), 8.19 (d, J = 8 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 23.8 (CH₃), 26.5 (CH₃), 28.4 (CH₃), 40.3 (CH₂), 68.0 (CH₂), 70.2 (CH₂), 70.3 (CH₂), 70.9 (CH₂), 77.5 (C), 79.2 (C), 116.9 (CH), 121.9 (CH), 125.5 (CH), 127.7 (C), 130.3 (CH), 139.6 (C), 155.9 (C), 168.8 (C), 170.7 (C), 175.1 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]⁺ calcd for C₂₂H₃₀N₂O₈Na 473.1900, found 473.1901; R_f (AcOEt/petroleum ether 1/1) 0.47.

Compound 4n. According to the general procedure, 4n was obtained (123 mg, yield: 66%) as a viscous oil from hydroxyoxindole 8a (64 mg, 0.312 mmol), Boc-[NH-(CH₂)₂O-(CH₂)₂OCH₂CO]₂OH (155 mg, 0.374 mmol), DCC (70.8 mg, 0.343 mmol), and DMAP (45.8 mg, 0.374 mmol): 1 H NMR (300 MHz, CDCl₃) δ 1.37 (s, 9H), 1.61 (s, 3H), 2.62 (s, 3H), 3.20–3.25 (m, 2H), 3.38–3.60 (m, 14H), 3.90 (s, 2H), 4.06, 4.15 (ABq, $J_{AB} = 16.8$ Hz, 2H), 5.15 (br s, 1H), 7.11-7.26 (m, 3H), 7.31 (t, J = 7.89 Hz, 1H), 8.19 (d, J = 8.1 Hz, 1H); 13 C NMR (75.5 MHz, CDCl₃) δ 23.8 (CH₃), 26.6 (CH₃), 28.4 (CH₃), 38.5 (CH₂), 40.3 (CH₂), 68.0 (CH₂), 67.0 (CH₂), 70.1 (CH₂), 70.4 (CH₂), 70.5 (CH₂), 70.8, (CH₂) 70.9 (CH₂), 77.5 (C), 79.2 (C), 116.9 (CH), 121.9 (CH), 125.5 (CH), 127.7 (C), 130.4 (CH), 139.6 (C), 156.0 (C), 168.7 (C), 170.0 (C), 170.7 (C), 175.1 (C); HRMS (ESI-TOF, $CH_2Cl_2/MeOH$ 95/5) m/z [M + Na]⁺ calcd for C₂₈H₄₁N₃O₁₁Na 618.2633, found 618.2633; R_f (AcOEt/MeOH 9/ 1): 0.51.

tert-Butyl rel-(3-(((S)-2-(R-1-Acetyl-2-oxo-3-phenylindolin-3-yl)-2phenylethyl)amino)-3-oxopropyl)carbamate (40). Step 1: To a mixture of nitro-oxindole 6d (130 mg, 0.364 mmol) and NiCl₂ (96 mg, 0.74 mmol) in absolute ethanol (0.7 mL) was added sodium borohydride (233 mg, 6.16 mmol). The black mixture was stirred at room temperature. The progress of the reaction was monitored by TLC. Three further portions of sodium borohydride (50 mg, 1.3 mmol) were added after stirring for 3, 5, and 7 h, respectively. After dilution with CH₂Cl₂ (30 mL), the mixture was washed with 10% aqueous sodium carbonate. The organic phase was dried over sodium sulfate and then concentrated in vacuo. Step 2: To the resulting residue in CH₂Cl₂ (0.7 mL) were added 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide (EDC) (64 μ L, 0.364 mmol) and Boc-NH(CH₂)₂CO₂H (69.6 mg, 0.368 mmol). The mixture was stirred overnight, diluted with CH₂Cl₂ (20 mL), and washed with 10% aqueous citric acid and then water. After drying on sodium sulfate and concentration in vacuo, the residue was chromatographed over silica gel (5 g, eluent 7/3 CH₂Cl₂/AcOEt) to afford tert-butyl rel-(3-oxo-3-((S)-2-((R)-2-oxo-3-phenylindolin-3-yl)-2-phenylethyl)amino)propyl)carbamate (100 mg, 55% yield from 6d) as a white solid: ¹H NMR (300 MHz, CDCl₃) δ 1.33 (s, 9H), 1.94–2.05 (m, 2H), 3.13, 3.17 (ABq, $J_{AB} = 6$ Hz, 2H), 3.73 (t, J = 6 Hz, 2H), 4.13 (t, J = 7.8 Hz, 1H), 4.99 (br s, 1H), 5.74 (t, J = 5.7 Hz, 1H), 6.61 (d, J = 7.5 Hz, 1H), 6.84-7.26 (m, 11H), 7.57 (d, J = 7.5 Hz, 2H), 8.50 (br s, 1H); 13 C NMR (75.5 MHz, CDCl₃) δ 28.4 (CH₃), 36.1 (CH₂), 36.7 (CH₂), 38.9 (CH₂), 51.4 (CH), 60.2 (C), 79.3 (C), 109.8 (CH), 122.2 (CH), 125.9 (CH), 127.2 (CH), 127.3 (CH), 127.5 (CH), 127.8 (CH), 128.1 (CH), 128.7 (CH), 129.5 (CH), 131.3 (C), 136.7 (C), 138.3 (C), 139.9 (C), 156.1 (C), 171.5 (C), 179.7 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]⁺ calcd for C₃₀H₃₃N₃O₄Na 522.2369, found 522.2369; R_f (AcOEt/petroleum ether 1/1) 0.18; mp 125–132 °C. Step 3: To tert-butyl rel-(3-oxo-3-(((S)-2-((R)-2-oxo-3-phenylindolin-n))))3-yl)-2-phenylethyl)amino)propyl)carbamate (48.5 mg, 0.097 mmol) in CH₂Cl₂ (0.2 mL) were added DMAP (14.3 mg, 0.012 mmol), Et₃N (31 μ L, 0.21 mmol) and acetyl chloride (16 μ L, 0.21 mmol). The resulting mixture was stirred for 2.5 h at room temperature, diluted by CH₂Cl₂, and washed by water. After drying on sodium sulfate, concentration in vacuo, and chromatography over silica gel (6g, eluent

95/5 CH₂Cl₂/AcOEt), the expected product **4o** (32.9 mg, 63% yield) was obtained as a white amorphous solid: 1 H NMR (300 MHz, CDCl₃, 1/9 mixture of Boc rotamers) δ 1.18, 1.32 (two s, 9H), 2.02 (t, J=6 Hz, 2H), 2.64 (s, 3H), 3.13, 3.17 (ABq, $J_{AB}=6$ Hz, 2H), 3.65–3.82 (m, 1H), 3.85–3.94 (m, 1H), 4.12 (dd, J=11.1, 4.5 Hz, 1H), 4.88 (br s, 1H), 5.32 (br s, 1H), 6.84–6.87 (m, 2H), 6.97–7.11 (m, 5H), 7.15–7.25 (m, 2H), 7.30–7.35 (m, 2H), 7.50–7.54 (m, 2H), 7.85–7.88 (m, 1H); 13 C NMR (75.5 MHz, CDCl₃) δ 27.0 (CH₃), 27.8 (minor CH₃), 28.4 (CH₃), 36.1 (CH₂), 36.5 (CH₂), 38.8 (CH₂), 51.7 (CH), 60.6 (C), 79.3 (C), 116.3 (CH), 124.7 (CH), 124.9 (CH), 127.1 (CH), 127.8 (CH), 128.1 (CH), 128.4 (CH), 129.1 (CH), 129.2 (CH), 130.6 (C), 135.6 (C), 138.0 (C), 138.8 (C), 155.9 (C), 170.4 (C), 171.6 (C), 178.9 (C); HRMS (ESI-TOF, MeOH) m/z [M + Na]⁺ calcd for C₃₂H₃₅N₃O₅Na 564.2474, found 564.2470; R_f (AcOEt/petroleum ether 1/1) 0.40.

ASSOCIATED CONTENT

S Supporting Information

X-ray data of **2b** and copies of ¹H and ¹³C spectra for all new compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

*E-mail: joelle.vidal@univ-rennes1.fr.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

D.S. thanks the French Ministry of Research for a Ph.D. fellowship. Thierry Roisnel and Vincent Dorcet (Centre de diffractométrie X, Institut des Sciences Chimiques de Rennes) are acknowledged for the X-ray structure determination.

REFERENCES

- (1) For reviews on the enantioselective synthesis of 3,3-disubstituted oxindoles, see: (a) Marti, C.; Carreira, E. M. Eur. J. Org. Chem. 2003, 2209. (b) Galliford, C. V.; Scheidt, K. A. Angew. Chem., Int. Ed. 2007, 46, 8748. (c) Trost, B. M.; Brennan, M. K. Synthesis 2009, 3003. (d) Millemaggi, A.; Taylor, R. J. K. Eur. J. Org. Chem. 2010, 4527. (e) Zhou, F.; Liu, Y.-L.; Zhou, J. Adv. Synth. Catal. 2010, 352, 1381. (f) Klein, J. E. M. N.; Taylor, R. J. K. Eur. J. Org. Chem. 2011, 6821. (g) Ball-Jones, N. R.; Badillo, J. J.; Franz, A. K. Org. Biomol. Chem. 2012, 10, 5165. (h) Kumar, A.; Chimni, S. S. RSC Adv. 2012, 2, 9748. (i) Dalpozzo, R.; Bartoli, G.; Bencivenni, G. Chem. Soc. Rev. 2012, 41, 7247. (j) Singh, G. S.; Desta, Z. Y. Chem. Rev. 2012, 112, 6104. (k) Singh, G. S.; Desta, Z. Y. In Chemistry and Pharmacology of Naturally Occurring Bioactive Compounds; Brahmachari, G., Ed.; CRC Press: Boca Raton, 2013; p 73. (1) Chauhan, P.; Chimni, S. S. Tetrahedron: Asymmetry 2013, 24, 343. (m) Hong, L.; Wang, R. Adv. Synth. Catal. 2013, 355, 1023. (n) Mohammadi, S.; Heiran, R.; Herrera, R. P.; Marqués-López, E. ChemCatChem 2013, 5, 2131. (o) Liu, Y.; Wang, H.; Wan, J. Asian J. Org. Chem. 2013, 2, 374. (p) Chen, L.; Yin, X.-P.; Wang, C.-H.; Zhou, J. Org. Biomol. Chem. 2014, 12, 6033.
- (2) Kohno, J.; Koguchi, Y.; Nishio, M.; Nakao, K.; Kuroda, M.; Shimizu, R.; Ohnuki, T.; Komatsubara, S. J. Org. Chem. 2000, 65, 990. (3) For reviews, see: (a) Genin, E.; Reboud-Ravaux, M.; Vidal, J. Curr. Top. Med. Chem. 2010, 10, 232. (b) Rentsch, A.; Landsberg, D.; Brodmann, T.; Bülow, L.; Girbig, A.-K.; Kalesse, M. Angew. Chem., Int. Ed. 2013, 52, 5450.
- (4) (a) Desvergne, A.; Genin, E.; Maréchal, X.; Gallastegui, N.; Dufau, L.; Richy, N.; Groll, M.; Vidal, J.; Reboud-Ravaux, M. J. Med. Chem. 2013, 56, 3367. (b) Groll, M.; Gallastegui, N.; Marechal, X.; Le Ravalec, V.; Basse, N.; Richy, N.; Genin, E.; Huber, R.; Moroder, L.; Vidal, J.; Reboud-Ravaux, M. ChemMedChem 2010, 5, 1701.

- (5) (a) Freter, K.; Weissbach, H.; Redfield, B.; Udenfriend, S.; Witkop, B. J. Am. Chem. Soc. 1958, 80, 983. (b) Wenkert, E.; Bernstein, B. S.; Udelhofen, J. H. J. Am. Chem. Soc. 1958, 80, 4899. (c) Islip, P. J.; White, A. C. J. Chem. Soc. 1964, 1201. (d) Nakagawa, M.; Maruyama, T.; Hirakoso, K.; Hino, T. Tetrahedron Lett. 1980, 21, 4839. (e) Nakagawa, M.; Kato, S.; Fukazawa, H.; Hasegawa, Y.; Miyazawa, J.; Hino, T. Tetrahedron Lett. 1985, 26, 5871. (f) Shishido, K.; Shitara, E.; Komatsu, H.; Hiroya, K.; Fukumoto, K.; Kametani, T. J. Org. Chem. 1986, 51, 3007. (g) Kawasaki, T.; Takamiya, W.; Okamoto, N.; Nagaoka, M.; Hirayama, T. Tetrahedron Lett. 2006, 47, 5379. (h) Kim, S. C.; Lee, K. Y.; Gowrisankar, S.; Kim, J. N. Bull. Korean Chem. Soc. 2006, 27, 1133. (i) Kim, S. C.; Gowrisankar, S.; Kim, J. N. Tetrahedron Lett. 2006, 47, 3463. (j) Movassaghi, M.; Schmidt, M. A.; Ashenhurst, J. A. Org. Lett. 2008, 10, 4009. (k) Wu, H.; Xue, F.; Xiao, X.; Qin, Y. J. Am. Chem. Soc. 2010, 132, 14052. (1) Qiu, J.; Zhang, J.-X.; Liu, S.; Hao, X.-J. Tetrahedron Lett. 2013, 54, 300.
- (6) For a similar isomerization leading to γ -lactones, see: Liu, Y.-L.; Wang, B.-L.; Cao, J.-J.; Chen, L.; Zhang, Y.-X.; Wang, C.; Zhou, J. *J. Am. Chem. Soc.* **2010**, *132*, 15176.
- (7) (a) Khuzhaev, V. U. Chem. Nat. Compd. 2004, 40, 516. (b) Chen, W.-B.; Du, X.-L.; Cun, L.-F.; Zhang, X.-M.; Yuan, W.-C. Tetrahedron 2010, 66, 1441.
- (8) Takayama, H.; Matsuda, Y.; Masubuchi, K.; Ishida, A.; Kitajima, M.; Aimi, N. *Tetrahedron* **2004**, *60*, 893.
- (9) Inoue, M.; Sakazaki, H.; Furuyama, H.; Hirama, M. Angew. Chem., Int. Ed. 2003, 42, 2654.
- (10) For reviews on lactam synthesis, see: (a) Natural Lactones and Lactams: Synthesis, Occurrence and Biological Activity; Janecki, T., Ed.; Wiley: New York, 2013. (b) Smith, M. B. In Science of Synthesis; Weinreb, S., Ed.; Georg Thieme Verlag: Stuttgart, 2005; Vol. 21, p 647. (c) Nubbemeyer, U. In Stereoselective Heterocyclic Synthesis III; Metz, P., Ed.; Topics in Current Chemistry; Springer-Verlag: Berlin, 2001; Vol. 216, p 125.
- (11) For difficult medium-sized lactam synthesis, see, for instance: (a) Ha, K.; Monbaliu, J-C. M.; Williams, B. C.; Pillai, G. G.; Ocampo, C. E.; Zeller, M.; Stevens, C. V.; Katritzky, A. R. *Org. Biomol. Chem.* **2012**, *10*, 8055. (b) Sharma, A.; Appukkuttan, P.; Van der Eycken, E. *Chem. Commun.* **2012**, *48*, 1623. (c) David, O.; Meester, W. J. N.; Bieräugel, H.; Schoemaker, H. E.; Hiemstra, H.; van Maarseveen, J. H. *Angew. Chem., Int. Ed.* **2003**, *42*, 4373.
- (12) For catalyzed asymmetric Michael addition of prochiral 3oxindoles to nitroolefins, see: (a) Bui, T.; Syed, S.; Barbas, C. F. J. Am. Chem. Soc. 2009, 131, 8758. (b) Kato, Y.; Furutachi, M.; Chen, Z.; Mitsunuma, H.; Matsunaga, S.; Shibasaki, M. J. Am. Chem. Soc. 2009, 131, 9168. (c) He, R.; Shirakawa, S.; Maruoka, K. J. Am. Chem. Soc. 2009, 131, 16620. (d) Li, X.; Zhang, B.; Xi, Z.-G.; Luo, S.; Cheng, J.-P. Adv. Synth. Catal. 2010, 352, 416. (e) Ding, M.; Zhou, F.; Qian, Z.-Q.; Zhou, J. Org. Biomol. Chem. 2010, 8, 2912. (f) Ding, M.; Zhou, F.; Liu, Y.-L.; Wang, C.-H.; Zhao, X.-L.; Zhou, J. Chem. Sci. 2011, 2, 2035. (g) Han, Y.-Y.; Wu, Z.-J.; Chen, W.-B.; Du, X.-L.; Zhang, X.-M.; Yuan, W.-C. Org. Lett. 2011, 13, 5064. (h) Liu, X.-L.; Wu, Z.-J.; Du, X.-L.; Zhang, X.-M.; Yuan, W.-C. J. Org. Chem. 2011, 76, 4008. (i) Chen, X.; Zhu, W.; Qian, W.; Feng, E.; Zhou, Y.; Wang, J.; Jiang, H.; Yao, Z.-J.; Liu, H. Adv. Synth. Catal. 2012, 354, 2151. (j) Wang, C.; Yang, X.; Enders, D. Chem.—Eur. J. 2012, 18, 4832. (k) Yang, W.; Wang, J.; Du, D.-M. Tetrahedron: Asymmetry 2012, 23, 972. (1) Retini, M.; Bergonzini, G.; Melchiorre, P. Chem. Commun. 2012, 48, 3336. (m) Noole, A.; Järving, I.; Werner, F.; Lopp, M.; Malkov, A.; Kanger, T. Org. Lett. 2012, 14, 4922. (n) Cui, B.-D.; Han, W.-Y.; Wu, Z.-J.; Zhang, X.-M.; Yuan, W.-C. J. Org. Chem. 2013, 78, 8833. (o) Zou, L.; Bao, X.; ma, Y.; Song, Y.; Qu, J.; Wang, B. Chem. Commun. 2014, 50, 5760. (p) Shirakawa, S.; Wang, L.; He, R.; Arimitsu, S.; Maruoka, K. Chem.—Asian J. 2014, 9, 1586.
- (13) Quintavalla, A.; Lanza, F.; Montroni, E.; Lombardo, M.; Trombini, C. J. Org. Chem. 2013, 78, 12049.
- (14) See, for instance: (a) Geoghegan, P.; O'Leary, P. *Tetrahedron: Asymmetry* **2010**, *21*, 867. (b) Bisol, T. B.; Bortoluzzi, A. J.; Sá, M. M. *J. Org. Chem.* **2011**, *76*, 948.
- (15) Neises, B.; Steglich, W. Angew. Chem., Int. Ed. 1978, 17, 522.

- (16) Ren, Q.; Huang, J.; Wang, L.; Li, W.; Liu, H.; Jiang, X.; Wang, J. ACS Catal. 2012, 2, 2622.
- (17) Clave, G.; Boutal, H.; Hoang, A.; Perraut, F.; Volland, H.; Renard, P.-Y.; Romieu, A. Org. Biomol. Chem. 2008, 6, 3065.
- (18) Chandra, K.; Dutta, D.; Das, A.; Basak, A. Bioorg. Med. Chem. 2010, 18, 8365.
- (19) Marsault, E.; Peterson, M. L. J. Med. Chem. 2011, 54, 1961.
- (20) Ranganathan, D.; Rao, C. B.; Ranganathan, S.; Mehrotra, A. K.; Iyengar, R. J. Org. Chem. 1980, 45, 1185.
- (21) Zhang, X.; Foote, C. S. J. Am. Chem. Soc. 1993, 115, 8867.
- (22) Iyer, R. A.; Hanna, P. E. Bioorg. Med. Chem. Lett. 1995, 5, 89.
- (23) Sakamoto, M.; Kobaru, S.; Kasashima, Y.; Mino, T.; Fujita, T. Tetrahedron Lett. 2005, 46, 4439.